{
  "version": "0.1.0",
  "scopes": [
    {
      "scope_id": "clinical_signal_03",
      "episodes": [
        {
          "episode_id": "clinical_signal_03_ep_001",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-04T10:00:00",
          "text": "## 2024-03-04 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 40\n- Active: 40\n- Screen Failures Cumulative: 2\n- Withdrawals Cumulative: 0\n\n#### Sites\n- Site 01: \n  - Enrolled: 4\n  - Active: 4\n  - Statin Concomitant: 1\n- Site 02: \n  - Enrolled: 3\n  - Active: 3\n  - Statin Concomitant: 0\n- Site 03: \n  - Enrolled: 3\n  - Active: 3\n  - Statin Concomitant: 0\n- Site 04: \n  - Enrolled: 2\n  - Active: 2\n  - Statin Concomitant: 0\n- Site 05: \n  - Enrolled: 3\n  - Active: 3\n  - Statin Concomitant: 0\n- Site 06: \n  - Enrolled: 2\n  - Active: 2\n  - Statin Concomitant: 0\n- Site 07: \n  - Enrolled: 4\n  - Active: 4\n  - Statin Concomitant: 1\n- Site 08: \n  - Enrolled: 3\n  - Active: 3\n  - Statin Concomitant: 0\n- Site 09: \n  - Enrolled: 3\n  - Active: 3\n  - Statin Concomitant: 0\n- Site 10: \n  - Enrolled: 2\n  - Active: 2\n  - Statin Concomitant: 0\n- Site 11: \n  - Enrolled: 3\n  - Active: 3\n  - Statin Concomitant: 0\n- Site 12: \n  - Enrolled: 3\n  - Active: 3\n  - Statin Concomitant: 0\n\n### Lab Panels\n- Statin Subgroup:\n  - N: 53\n  - ALT (U/L) Mean: 25.5\n  - ALT (U/L) Median: 22.7\n  - AST (U/L) Mean: 26.4\n  - AST (U/L) Median: 24.4\n  - Bilirubin (mg/dL) Mean: 0.78\n  - Bilirubin (mg/dL) Median: 0.74\n  - ALP (U/L) Mean: 84.9\n  - ALP (U/L) Median: 76.7\n  - Creatinine (mg/dL) Mean: 1.06\n  - Creatinine (mg/dL) Median: 0.95\n  - BUN (mg/dL) Mean: 16.9\n  - BUN (mg/dL) Median: 15.1\n  - WBC (K) Mean: 5.9\n  - WBC (K) Median: 7.6\n  - Platelets (K) Mean: 233\n  - Platelets (K) Median: 242\n- Non-Statin Subgroup:\n  - N: 131\n  - ALT (U/L) Mean: 29.9\n  - ALT (U/L) Median: 28.9\n  - AST (U/L) Mean: 26.4\n  - AST (U/L) Median: 25.9\n  - Bilirubin (mg/dL) Mean: 0.73\n  - Bilirubin (mg/dL) Median: 0.7\n  - ALP (U/L) Mean: 71.9\n  - ALP (U/L) Median: 68.2\n  - Creatinine (mg/dL) Mean: 1.1\n  - Creatinine (mg/dL) Median: 0.98\n  - BUN (mg/dL) Mean: 16.8\n  - BUN (mg/dL) Median: 13.9\n  - WBC (K) Mean: 6.0\n  - WBC (K) Median: 7.8\n  - Platelets (K) Mean: 218\n  - Platelets (K) Median: 256\n\n### Adverse Events\n- AE ID: AE-0001\n  - Description: upper respiratory infection\n  - Grade: 1\n  - Relatedness: not related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0002\n  - Description: nausea\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: non_statin\n- AE ID: AE-0003\n  - Description: headache\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0004\n  - Description: diarrhea\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 27\n- Metformin Count: 23\n- PPI Count: 18\n- NSAID Count: 12\n- Other Count: 32\n\n### Protocol Deviations\n- PD ID: PD-001\n  - Description: Missed visit window (1 days late)\n  - Severity: minor\n  - Site: site_05\n- PD ID: PD-002\n  - Description: IP temperature excursion during shipment, 2h out of range\n  - Severity: moderate\n  - Site: site_11\n- PD ID: PD-003\n  - Description: Lab sample mislabeled, corrected same day\n  - Severity: minor\n  - Site: site_08\n\n### Investigator Notes\n- IEC/IRB annual renewal submitted on schedule\n- Study drug accountability reconciled, no discrepancies\n\n### Events\n- Central lab courier pickup schedule adjusted for holiday\n- Drug accountability audit at Site 08: no discrepancies\n\n### Notes\n- Week 1: Enrollment proceeding per plan. Lab panels within reference ranges. Routine AEs only.",
          "meta": {
            "episode_type": "signal",
            "phase": "baseline",
            "signal_density": "none"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_002",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-11T10:00:00",
          "text": "## 2024-03-11 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 60\n- Active: 60\n- Screen Failures Cumulative: 4\n- Withdrawals Cumulative: 0\n\n#### Sites\n- Site 01 Enrolled: 6\n- Site 01 Active: 6\n- Site 01 Statin Concomitant: 1\n- Site 02 Enrolled: 4\n- Site 02 Active: 4\n- Site 02 Statin Concomitant: 1\n- Site 03 Enrolled: 5\n- Site 03 Active: 5\n- Site 03 Statin Concomitant: 1\n- Site 04 Enrolled: 4\n- Site 04 Active: 4\n- Site 04 Statin Concomitant: 1\n- Site 05 Enrolled: 5\n- Site 05 Active: 5\n- Site 05 Statin Concomitant: 1\n- Site 06 Enrolled: 3\n- Site 06 Active: 3\n- Site 06 Statin Concomitant: 1\n- Site 07 Enrolled: 6\n- Site 07 Active: 6\n- Site 07 Statin Concomitant: 1\n- Site 08 Enrolled: 4\n- Site 08 Active: 4\n- Site 08 Statin Concomitant: 1\n- Site 09 Enrolled: 5\n- Site 09 Active: 5\n- Site 09 Statin Concomitant: 1\n- Site 10 Enrolled: 4\n- Site 10 Active: 4\n- Site 10 Statin Concomitant: 1\n- Site 11 Enrolled: 5\n- Site 11 Active: 5\n- Site 11 Statin Concomitant: 1\n- Site 12 Enrolled: 4\n- Site 12 Active: 4\n- Site 12 Statin Concomitant: 1\n\n### Lab Panels\n- Statin Subgroup N: 53\n- Statin Subgroup ALT (U/L) Mean: 26.8\n- Statin Subgroup ALT (U/L) Median: 26.3\n- Statin Subgroup AST (U/L) Mean: 22.1\n- Statin Subgroup AST (U/L) Median: 20.8\n- Statin Subgroup Bilirubin (mg/dL) Mean: 0.73\n- Statin Subgroup Bilirubin (mg/dL) Median: 0.72\n- Statin Subgroup ALP (U/L) Mean: 71.0\n- Statin Subgroup ALP (U/L) Median: 75.0\n- Statin Subgroup Creatinine (mg/dL) Mean: 0.85\n- Statin Subgroup Creatinine (mg/dL) Median: 0.93\n- Statin Subgroup BUN (mg/dL) Mean: 16.6\n- Statin Subgroup BUN (mg/dL) Median: 16.0\n- Statin Subgroup WBC (K) Mean: 7.5\n- Statin Subgroup WBC (K) Median: 7.0\n- Statin Subgroup Platelets (K) Mean: 236\n- Statin Subgroup Platelets (K) Median: 249\n- Non-Statin Subgroup N: 122\n- Non-Statin Subgroup ALT (U/L) Mean: 29.7\n- Non-Statin Subgroup ALT (U/L) Median: 28.0\n- Non-Statin Subgroup AST (U/L) Mean: 20.7\n- Non-Statin Subgroup AST (U/L) Median: 20.0\n- Non-Statin Subgroup Bilirubin (mg/dL) Mean: 0.9\n- Non-Statin Subgroup Bilirubin (mg/dL) Median: 0.89\n- Non-Statin Subgroup ALP (U/L) Mean: 56.7\n- Non-Statin Subgroup ALP (U/L) Median: 60.5\n- Non-Statin Subgroup Creatinine (mg/dL) Mean: 0.92\n- Non-Statin Subgroup Creatinine (mg/dL) Median: 0.82\n- Non-Statin Subgroup BUN (mg/dL) Mean: 16.0\n- Non-Statin Subgroup BUN (mg/dL) Median: 13.8\n- Non-Statin Subgroup WBC (K) Mean: 7.5\n- Non-Statin Subgroup WBC (K) Median: 6.8\n- Non-Statin Subgroup Platelets (K) Mean: 233\n- Non-Statin Subgroup Platelets (K) Median: 220\n\n### Adverse Events\n- AE ID: AE-0005, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0006, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0007, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 27\n- Metformin Count: 23\n- PPI Count: 18\n- NSAID Count: 12\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-004, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_02\n- PD ID: PD-005, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_05\n- PD ID: PD-006, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_12\n\n### Investigator Notes\n- Site pharmacy inventory verified\n- Subject retention rate within protocol targets\n- Study drug accountability reconciled, no discrepancies\n\n### Events\n- Data management plan revision v2.5 distributed\n- Site 12 pharmacy temperature log reviewed: compliant\n\n### Notes\n- Week 2: Enrollment proceeding per plan. Lab panels within reference ranges. Routine AEs only.",
          "meta": {
            "episode_type": "signal",
            "phase": "baseline",
            "signal_density": "none"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_003",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-18T10:00:00",
          "text": "## 2024-03-18 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 80\n- Active: 80\n- Screen Failures Cumulative: 5\n- Withdrawals Cumulative: 0\n\n#### Sites\n- Site 01 Enrolled: 8\n- Site 01 Active: 8\n- Site 01 Statin Concomitant: 2\n- Site 02 Enrolled: 6\n- Site 02 Active: 6\n- Site 02 Statin Concomitant: 1\n- Site 03 Enrolled: 7\n- Site 03 Active: 7\n- Site 03 Statin Concomitant: 1\n- Site 04 Enrolled: 5\n- Site 04 Active: 5\n- Site 04 Statin Concomitant: 1\n- Site 05 Enrolled: 6\n- Site 05 Active: 6\n- Site 05 Statin Concomitant: 1\n- Site 06 Enrolled: 4\n- Site 06 Active: 4\n- Site 06 Statin Concomitant: 1\n- Site 07 Enrolled: 8\n- Site 07 Active: 8\n- Site 07 Statin Concomitant: 2\n- Site 08 Enrolled: 6\n- Site 08 Active: 6\n- Site 08 Statin Concomitant: 1\n- Site 09 Enrolled: 6\n- Site 09 Active: 6\n- Site 09 Statin Concomitant: 1\n- Site 10 Enrolled: 5\n- Site 10 Active: 5\n- Site 10 Statin Concomitant: 1\n- Site 11 Enrolled: 7\n- Site 11 Active: 7\n- Site 11 Statin Concomitant: 1\n- Site 12 Enrolled: 6\n- Site 12 Active: 6\n- Site 12 Statin Concomitant: 1\n\n### Lab Panels\n- Statin Subgroup N: 55\n- Statin Subgroup ALT (U/L) Mean: 26.0\n- Statin Subgroup ALT (U/L) Median: 24.3\n- Statin Subgroup AST (U/L) Mean: 27.9\n- Statin Subgroup AST (U/L) Median: 25.9\n- Statin Subgroup Bilirubin (mg/dL) Mean: 0.59\n- Statin Subgroup Bilirubin (mg/dL) Median: 0.56\n- Statin Subgroup ALP (U/L) Mean: 79.3\n- Statin Subgroup ALP (U/L) Median: 57.2\n- Statin Subgroup Creatinine (mg/dL) Mean: 1.04\n- Statin Subgroup Creatinine (mg/dL) Median: 0.9\n- Statin Subgroup BUN (mg/dL) Mean: 16.6\n- Statin Subgroup BUN (mg/dL) Median: 14.8\n- Statin Subgroup WBC (K) Mean: 5.9\n- Statin Subgroup WBC (K) Median: 6.5\n- Statin Subgroup Platelets (K) Mean: 245\n- Statin Subgroup Platelets (K) Median: 220\n- Non-Statin Subgroup N: 124\n- Non-Statin Subgroup ALT (U/L) Mean: 21.2\n- Non-Statin Subgroup ALT (U/L) Median: 20.6\n- Non-Statin Subgroup AST (U/L) Mean: 29.1\n- Non-Statin Subgroup AST (U/L) Median: 28.2\n- Non-Statin Subgroup Bilirubin (mg/dL) Mean: 0.54\n- Non-Statin Subgroup Bilirubin (mg/dL) Median: 0.49\n- Non-Statin Subgroup ALP (U/L) Mean: 73.5\n- Non-Statin Subgroup ALP (U/L) Median: 63.4\n- Non-Statin Subgroup Creatinine (mg/dL) Mean: 1.0\n- Non-Statin Subgroup Creatinine (mg/dL) Median: 0.99\n- Non-Statin Subgroup BUN (mg/dL) Mean: 17.2\n- Non-Statin Subgroup BUN (mg/dL) Median: 14.5\n- Non-Statin Subgroup WBC (K) Mean: 5.6\n- Non-Statin Subgroup WBC (K) Median: 6.4\n- Non-Statin Subgroup Platelets (K) Mean: 229\n- Non-Statin Subgroup Platelets (K) Median: 240\n\n### Adverse Events\n- AE ID: AE-0008, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0009, Description: headache, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0010, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 51\n- ACE Inhibitor Count: 28\n- Metformin Count: 21\n- PPI Count: 19\n- NSAID Count: 13\n- Other Count: 32\n\n### Protocol Deviations\n- PD ID: PD-007, Description: Incorrect lab panel order, repeated, Severity: minor, Site: site_03\n- PD ID: PD-008, Description: Concomitant medication not recorded at visit, Severity: minor, Site: site_04\n\n### Investigator Notes\n- All CRFs current through prior visit cycle\n- Query resolution rate at 94%\n- Lab kits inventory adequate for next 4 weeks\n\n### Events\n- Central lab courier pickup schedule adjusted for holiday\n- Bioanalytical lab shipment tracking confirmed for 2 samples\n- Medical monitor weekly call completed\n\n### Notes\n- Week 3: Enrollment proceeding per plan. Lab panels within reference ranges. Routine AEs only.",
          "meta": {
            "episode_type": "signal",
            "phase": "baseline",
            "signal_density": "none"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_004",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-03-25T10:00:00",
          "text": "## 2024-03-25 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 100\n- Active: 98\n- Screen Failures Cumulative: 11\n- Withdrawals Cumulative: 2\n\n#### Sites\n- Site 01\n  - Enrolled: 10\n  - Active: 10\n  - Statin Concomitant: 2\n- Site 02\n  - Enrolled: 7\n  - Active: 7\n  - Statin Concomitant: 1\n- Site 03\n  - Enrolled: 9\n  - Active: 9\n  - Statin Concomitant: 2\n- Site 04\n  - Enrolled: 6\n  - Active: 6\n  - Statin Concomitant: 1\n- Site 05\n  - Enrolled: 8\n  - Active: 8\n  - Statin Concomitant: 2\n- Site 06\n  - Enrolled: 5\n  - Active: 5\n  - Statin Concomitant: 1\n- Site 07\n  - Enrolled: 11\n  - Active: 11\n  - Statin Concomitant: 3\n- Site 08\n  - Enrolled: 7\n  - Active: 7\n  - Statin Concomitant: 2\n- Site 09\n  - Enrolled: 8\n  - Active: 8\n  - Statin Concomitant: 2\n- Site 10\n  - Enrolled: 6\n  - Active: 6\n  - Statin Concomitant: 2\n- Site 11\n  - Enrolled: 9\n  - Active: 9\n  - Statin Concomitant: 2\n- Site 12\n  - Enrolled: 7\n  - Active: 7\n  - Statin Concomitant: 1\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 24.6\n- ALT (U/L) Median: 23.8\n- AST (U/L) Mean: 23.6\n- AST (U/L) Median: 23.2\n- Bilirubin (mg/dL) Mean: 0.86\n- Bilirubin (mg/dL) Median: 0.84\n- ALP (U/L) Mean: 73.7\n- ALP (U/L) Median: 63.8\n- Creatinine (mg/dL) Mean: 1.06\n- Creatinine (mg/dL) Median: 0.92\n- BUN (mg/dL) Mean: 13.3\n- BUN (mg/dL) Median: 13.0\n- WBC (K) Mean: 8.2\n- WBC (K) Median: 5.5\n- Platelets (K) Mean: 235\n- Platelets (K) Median: 234\n\n#### Non-Statin Subgroup\n- N: 122\n- ALT (U/L) Mean: 24.6\n- ALT (U/L) Median: 23.1\n- AST (U/L) Mean: 24.7\n- AST (U/L) Median: 22.8\n- Bilirubin (mg/dL) Mean: 0.7\n- Bilirubin (mg/dL) Median: 0.68\n- ALP (U/L) Mean: 59.4\n- ALP (U/L) Median: 54.2\n- Creatinine (mg/dL) Mean: 1.01\n- Creatinine (mg/dL) Median: 0.8\n- BUN (mg/dL) Mean: 14.8\n- BUN (mg/dL) Median: 11.5\n- WBC (K) Mean: 7.6\n- WBC (K) Median: 7.0\n- Platelets (K) Mean: 243\n- Platelets (K) Median: 244\n\n### Adverse Events\n- AE ID: AE-0011, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0012, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 28\n- Metformin Count: 23\n- PPI Count: 18\n- NSAID Count: 13\n- Other Count: 37\n\n### Protocol Deviations\n- PD ID: PD-009, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_05\n- PD ID: PD-010, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_06\n- PD ID: PD-011, Description: Eligibility criterion reassessed, subject confirmed eligible, Severity: minor, Site: site_10\n\n### Investigator Notes\n- No new safety signals identified this week by local PI\n- Site pharmacy inventory verified\n- Query resolution rate at 94%\n\n### Events\n- Data management plan revision v2.2 distributed\n- IVRS system update deployed, randomization unaffected\n\n### Notes\n- Week 4: Enrollment proceeding per plan. Lab panels within reference ranges. Routine AEs only.",
          "meta": {
            "episode_type": "signal",
            "phase": "baseline",
            "signal_density": "none"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_005",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-01T10:00:00",
          "text": "## 2024-04-01 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 120\n- Active: 118\n- Screen Failures Cumulative: 11\n- Withdrawals Cumulative: 2\n\n#### Sites\n- Site 01 Enrolled: 12\n- Site 01 Active: 12\n- Site 01 Statin Concomitant: 4\n- Site 02 Enrolled: 9\n- Site 02 Active: 9\n- Site 02 Statin Concomitant: 3\n- Site 03 Enrolled: 11\n- Site 03 Active: 11\n- Site 03 Statin Concomitant: 3\n- Site 04 Enrolled: 8\n- Site 04 Active: 8\n- Site 04 Statin Concomitant: 2\n- Site 05 Enrolled: 10\n- Site 05 Active: 10\n- Site 05 Statin Concomitant: 3\n- Site 06 Enrolled: 7\n- Site 06 Active: 7\n- Site 06 Statin Concomitant: 2\n- Site 07 Enrolled: 13\n- Site 07 Active: 13\n- Site 07 Statin Concomitant: 3\n- Site 08 Enrolled: 9\n- Site 08 Active: 9\n- Site 08 Statin Concomitant: 2\n- Site 09 Enrolled: 10\n- Site 09 Active: 10\n- Site 09 Statin Concomitant: 3\n- Site 10 Enrolled: 8\n- Site 10 Active: 8\n- Site 10 Statin Concomitant: 2\n- Site 11 Enrolled: 11\n- Site 11 Active: 11\n- Site 11 Statin Concomitant: 3\n- Site 12 Enrolled: 9\n- Site 12 Active: 9\n- Site 12 Statin Concomitant: 2\n\n### Lab Panels\n#### Statin Subgroup\n- N: 56\n- ALT (U/L) Mean: 26.3\n- ALT (U/L) Median: 25.5\n- AST (U/L) Mean: 22.6\n- AST (U/L) Median: 22.4\n- Bilirubin (mg/dL) Mean: 0.67\n- Bilirubin (mg/dL) Median: 0.65\n- ALP (U/L) Mean: 68.6\n- ALP (U/L) Median: 79.7\n- Creatinine (mg/dL) Mean: 1.02\n- Creatinine (mg/dL) Median: 0.97\n- BUN (mg/dL) Mean: 17.6\n- BUN (mg/dL) Median: 11.1\n- WBC (K) Mean: 6.2\n- WBC (K) Median: 6.1\n- Platelets (K) Mean: 258\n- Platelets (K) Median: 256\n\n#### Non-Statin Subgroup\n- N: 128\n- ALT (U/L) Mean: 31.5\n- ALT (U/L) Median: 30.6\n- AST (U/L) Mean: 27.2\n- AST (U/L) Median: 25.6\n- Bilirubin (mg/dL) Mean: 0.7\n- Bilirubin (mg/dL) Median: 0.67\n- ALP (U/L) Mean: 73.4\n- ALP (U/L) Median: 53.9\n- Creatinine (mg/dL) Mean: 1.01\n- Creatinine (mg/dL) Median: 0.98\n- BUN (mg/dL) Mean: 13.0\n- BUN (mg/dL) Median: 16.0\n- WBC (K) Mean: 8.4\n- WBC (K) Median: 6.4\n- Platelets (K) Mean: 251\n- Platelets (K) Median: 246\n\n### Adverse Events\n- AE ID: AE-0013, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0014, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0015, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0016, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n\n### Concomitant Meds\n- Statin Count: 53\n- ACE Inhibitor Count: 28\n- Metformin Count: 21\n- PPI Count: 17\n- NSAID Count: 12\n- Other Count: 36\n\n### Protocol Deviations\n- PD ID: PD-012, Description: Lab sample mislabeled, corrected same day, Severity: minor, Site: site_07\n- PD ID: PD-013, Description: Lab sample mislabeled, corrected same day, Severity: minor, Site: site_05\n\n### Investigator Notes\n- IEC/IRB annual renewal submitted on schedule\n- Study drug accountability reconciled, no discrepancies\n\n### Events\n- IVRS system update deployed, randomization unaffected\n- EDC system maintenance window: 2h downtime Saturday 02:00 UTC\n\n### Notes\n- Week 5: Enrollment target met. All hepatic and renal panels within normal limits. 2 minor protocol deviations.",
          "meta": {
            "episode_type": "signal",
            "phase": "baseline",
            "signal_density": "none"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_006",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-08T10:00:00",
          "text": "## 2024-04-08 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 140\n- Active: 137\n- Screen Failures Cumulative: 11\n- Withdrawals Cumulative: 3\n\n#### Sites\n- Site 01 Enrolled: 14\n- Site 01 Active: 14\n- Site 01 Statin Concomitant: 4\n- Site 02 Enrolled: 10\n- Site 02 Active: 10\n- Site 02 Statin Concomitant: 3\n- Site 03 Enrolled: 18\n- Site 03 Active: 17\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 9\n- Site 04 Active: 9\n- Site 04 Statin Concomitant: 2\n- Site 05 Enrolled: 11\n- Site 05 Active: 11\n- Site 05 Statin Concomitant: 3\n- Site 06 Enrolled: 8\n- Site 06 Active: 8\n- Site 06 Statin Concomitant: 2\n- Site 07 Enrolled: 15\n- Site 07 Active: 15\n- Site 07 Statin Concomitant: 4\n- Site 08 Enrolled: 10\n- Site 08 Active: 10\n- Site 08 Statin Concomitant: 3\n- Site 09 Enrolled: 11\n- Site 09 Active: 11\n- Site 09 Statin Concomitant: 2\n- Site 10 Enrolled: 9\n- Site 10 Active: 9\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 13\n- Site 11 Active: 13\n- Site 11 Statin Concomitant: 4\n- Site 12 Enrolled: 10\n- Site 12 Active: 10\n- Site 12 Statin Concomitant: 3\n\n### Lab Panels\n- Statin Subgroup N: 53\n- Statin Subgroup ALT (U/L) Mean: 26.1\n- Statin Subgroup ALT (U/L) Median: 24.7\n- Statin Subgroup AST (U/L) Mean: 26.1\n- Statin Subgroup AST (U/L) Median: 25.3\n- Statin Subgroup Bilirubin (mg/dL) Mean: 0.83\n- Statin Subgroup Bilirubin (mg/dL) Median: 0.8\n- Statin Subgroup ALP (U/L) Mean: 61.2\n- Statin Subgroup ALP (U/L) Median: 62.5\n- Statin Subgroup Creatinine (mg/dL) Mean: 1.0\n- Statin Subgroup Creatinine (mg/dL) Median: 1.0\n- Statin Subgroup BUN (mg/dL) Mean: 13.6\n- Statin Subgroup BUN (mg/dL) Median: 14.3\n- Statin Subgroup WBC (K) Mean: 5.7\n- Statin Subgroup WBC (K) Median: 7.4\n- Statin Subgroup Platelets (K) Mean: 253\n- Statin Subgroup Platelets (K) Median: 229\n- Non-Statin Subgroup N: 131\n- Non-Statin Subgroup ALT (U/L) Mean: 22.6\n- Non-Statin Subgroup ALT (U/L) Median: 22.0\n- Non-Statin Subgroup AST (U/L) Mean: 28.8\n- Non-Statin Subgroup AST (U/L) Median: 28.1\n- Non-Statin Subgroup Bilirubin (mg/dL) Mean: 0.48\n- Non-Statin Subgroup Bilirubin (mg/dL) Median: 0.44\n- Non-Statin Subgroup ALP (U/L) Mean: 72.8\n- Non-Statin Subgroup ALP (U/L) Median: 59.0\n- Non-Statin Subgroup Creatinine (mg/dL) Mean: 0.83\n- Non-Statin Subgroup Creatinine (mg/dL) Median: 0.99\n- Non-Statin Subgroup BUN (mg/dL) Mean: 13.5\n- Non-Statin Subgroup BUN (mg/dL) Median: 13.3\n- Non-Statin Subgroup WBC (K) Mean: 7.4\n- Non-Statin Subgroup WBC (K) Median: 6.4\n- Non-Statin Subgroup Platelets (K) Mean: 249\n- Non-Statin Subgroup Platelets (K) Median: 226\n\n### Adverse Events\n- AE ID: AE-0017, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0018, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0019, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 55\n- ACE Inhibitor Count: 27\n- Metformin Count: 21\n- PPI Count: 17\n- NSAID Count: 12\n- Other Count: 38\n\n### Protocol Deviations\n- PD ID: PD-014, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_10\n- PD ID: PD-015, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_12\n- PD ID: PD-016, Description: Lab sample mislabeled, corrected same day, Severity: minor, Site: site_04\n\n### Investigator Notes\n- All CRFs current through prior visit cycle\n- Query resolution rate at 94%\n\n### Events\n- IRT randomization system verified, no anomalies\n- Bioanalytical lab shipment tracking confirmed for 1 samples\n- CRO quarterly oversight report submitted\n\n### Notes\n- Week 6: Enrollment target met. All hepatic and renal panels within normal limits. 4 minor protocol deviations.",
          "meta": {
            "episode_type": "signal",
            "phase": "baseline",
            "signal_density": "none"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_007",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-15T10:00:00",
          "text": "## 2024-04-15 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 160\n- Active: 156\n- Screen Failures Cumulative: 15\n- Withdrawals Cumulative: 4\n\n#### Sites\n- Site 01 Enrolled: 16\n- Site 01 Active: 16\n- Site 01 Statin Concomitant: 4\n- Site 02 Enrolled: 12\n- Site 02 Active: 12\n- Site 02 Statin Concomitant: 3\n- Site 03 Enrolled: 15\n- Site 03 Active: 15\n- Site 03 Statin Concomitant: 4\n- Site 04 Enrolled: 10\n- Site 04 Active: 10\n- Site 04 Statin Concomitant: 2\n- Site 05 Enrolled: 13\n- Site 05 Active: 13\n- Site 05 Statin Concomitant: 3\n- Site 06 Enrolled: 9\n- Site 06 Active: 9\n- Site 06 Statin Concomitant: 2\n- Site 07 Enrolled: 17\n- Site 07 Active: 17\n- Site 07 Statin Concomitant: 4\n- Site 08 Enrolled: 12\n- Site 08 Active: 12\n- Site 08 Statin Concomitant: 3\n- Site 09 Enrolled: 13\n- Site 09 Active: 13\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 10\n- Site 10 Active: 10\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 15\n- Site 11 Active: 15\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 12\n- Site 12 Active: 12\n- Site 12 Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 26.8\n- ALT (U/L) Median: 24.1\n- AST (U/L) Mean: 27.3\n- AST (U/L) Median: 26.7\n- Bilirubin (mg/dL) Mean: 0.64\n- Bilirubin (mg/dL) Median: 0.63\n- ALP (U/L) Mean: 80.7\n- ALP (U/L) Median: 63.0\n- Creatinine (mg/dL) Mean: 1.01\n- Creatinine (mg/dL) Median: 0.91\n- BUN (mg/dL) Mean: 15.3\n- BUN (mg/dL) Median: 16.6\n- WBC (K) Mean: 7.0\n- WBC (K) Median: 6.1\n- Platelets (K) Mean: 239\n- Platelets (K) Median: 248\n\n#### Non-Statin Subgroup\n- N: 120\n- ALT (U/L) Mean: 30.1\n- ALT (U/L) Median: 29.6\n- AST (U/L) Mean: 24.4\n- AST (U/L) Median: 24.3\n- Bilirubin (mg/dL) Mean: 0.76\n- Bilirubin (mg/dL) Median: 0.74\n- ALP (U/L) Mean: 56.6\n- ALP (U/L) Median: 50.4\n- Creatinine (mg/dL) Mean: 0.91\n- Creatinine (mg/dL) Median: 0.95\n- BUN (mg/dL) Mean: 17.1\n- BUN (mg/dL) Median: 15.7\n- WBC (K) Mean: 8.2\n- WBC (K) Median: 7.0\n- Platelets (K) Mean: 248\n- Platelets (K) Median: 226\n\n### Adverse Events\n- AE ID: AE-0020, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0021, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0022, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 53\n- ACE Inhibitor Count: 30\n- Metformin Count: 22\n- PPI Count: 19\n- NSAID Count: 11\n- Other Count: 32\n\n### Protocol Deviations\n- PD ID: PD-017, Description: Concomitant medication not recorded at visit, Severity: minor, Site: site_05\n- PD ID: PD-018, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_12\n\n### Investigator Notes\n- All SAE narratives submitted within reporting window\n- Study drug accountability reconciled, no discrepancies\n\n### Events\n- Site 04 pharmacy temperature log reviewed: compliant\n- CRO quarterly oversight report submitted\n- EDC system maintenance window: 2h downtime Saturday 02:00 UTC\n\n### Notes\n- Week 7: Enrollment target met.\n- All hepatic and renal panels within normal limits.\n- 3 minor protocol deviations.",
          "meta": {
            "episode_type": "signal",
            "phase": "baseline",
            "signal_density": "none"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_008",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-22T10:00:00",
          "text": "## 2024-04-22 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 180\n- Active: 177\n- Screen Failures Cumulative: 13\n- Withdrawals Cumulative: 3\n\n#### Sites\n- Site 01 Enrolled: 18\n- Site 01 Active: 18\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 13\n- Site 02 Active: 13\n- Site 02 Statin Concomitant: 3\n- Site 03 Enrolled: 16\n- Site 03 Active: 16\n- Site 03 Statin Concomitant: 4\n- Site 04 Enrolled: 12\n- Site 04 Active: 12\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 15\n- Site 05 Active: 15\n- Site 05 Statin Concomitant: 3\n- Site 06 Enrolled: 10\n- Site 06 Active: 10\n- Site 06 Statin Concomitant: 2\n- Site 07 Enrolled: 19\n- Site 07 Active: 19\n- Site 07 Statin Concomitant: 5\n- Site 08 Enrolled: 13\n- Site 08 Active: 13\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 15\n- Site 09 Active: 15\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 12\n- Site 10 Active: 12\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 16\n- Site 11 Active: 16\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 13\n- Site 12 Active: 13\n- Site 12 Statin Concomitant: 3\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 25.0\n- ALT (U/L) Median: 22.3\n- AST (U/L) Mean: 20.6\n- AST (U/L) Median: 19.0\n- Bilirubin (mg/dL) Mean: 0.73\n- Bilirubin (mg/dL) Median: 0.7\n- ALP (U/L) Mean: 73.1\n- ALP (U/L) Median: 76.4\n- Creatinine (mg/dL) Mean: 0.81\n- Creatinine (mg/dL) Median: 0.83\n- BUN (mg/dL) Mean: 15.6\n- BUN (mg/dL) Median: 12.5\n- WBC (K) Mean: 6.0\n- WBC (K) Median: 6.3\n- Platelets (K) Mean: 242\n- Platelets (K) Median: 244\n\n#### Non-Statin Subgroup\n- N: 130\n- ALT (U/L) Mean: 28.6\n- ALT (U/L) Median: 26.8\n- AST (U/L) Mean: 22.5\n- AST (U/L) Median: 20.5\n- Bilirubin (mg/dL) Mean: 0.57\n- Bilirubin (mg/dL) Median: 0.54\n- ALP (U/L) Mean: 50.6\n- ALP (U/L) Median: 66.5\n- Creatinine (mg/dL) Mean: 1.07\n- Creatinine (mg/dL) Median: 0.83\n- BUN (mg/dL) Mean: 17.3\n- BUN (mg/dL) Median: 16.2\n- WBC (K) Mean: 6.8\n- WBC (K) Median: 5.6\n- Platelets (K) Mean: 238\n- Platelets (K) Median: 233\n\n### Adverse Events\n- AE ID: AE-0023, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0024, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n\n### Concomitant Meds\n- Statin Count: 56\n- ACE Inhibitor Count: 29\n- Metformin Count: 23\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 33\n\n### Protocol Deviations\n- PD ID: PD-019, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_09\n- PD ID: PD-020, Description: Concomitant medication not recorded at visit, Severity: minor, Site: site_04\n\n### Investigator Notes\n- Study drug accountability reconciled, no discrepancies\n- All SAE narratives submitted within reporting window\n- No new safety signals identified this week by local PI\n\n### Events\n- Site 06 monitoring visit completed, 2 findings\n- Regulatory submission packet sent to Site 05\n- IP resupply shipped to Sites 11, 12\n\n### Notes\n- Week 8: Enrollment target met. All hepatic and renal panels within normal limits. 2 minor protocol deviations.",
          "meta": {
            "episode_type": "signal",
            "phase": "baseline",
            "signal_density": "none"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_009",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-04-29T10:00:00",
          "text": "## 2024-04-29 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 185\n- Active: 180\n- Screen Failures Cumulative: 22\n- Withdrawals Cumulative: 5\n\n#### Sites\n- Site 01 Enrolled: 18\n- Site 01 Active: 18\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 14\n- Site 02 Active: 14\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 17\n- Site 03 Active: 17\n- Site 03 Statin Concomitant: 4\n- Site 04 Enrolled: 12\n- Site 04 Active: 12\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 15\n- Site 05 Active: 15\n- Site 05 Statin Concomitant: 4\n- Site 06 Enrolled: 11\n- Site 06 Active: 11\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 20\n- Site 07 Active: 20\n- Site 07 Statin Concomitant: 5\n- Site 08 Enrolled: 14\n- Site 08 Active: 14\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 15\n- Site 09 Active: 15\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 12\n- Site 10 Active: 12\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 17\n- Site 11 Active: 17\n- Site 11 Statin Concomitant: 4\n- Site 12 Enrolled: 14\n- Site 12 Active: 14\n- Site 12 Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 54\n- ALT (U/L) Mean: 32.3\n- ALT (U/L) Median: 31.9\n- AST (U/L) Mean: 31.2\n- AST (U/L) Median: 31.2\n- Bilirubin (mg/dL) Mean: 0.56\n- Bilirubin (mg/dL) Median: 0.56\n- ALP (U/L) Mean: 66.5\n- ALP (U/L) Median: 70.2\n- Creatinine (mg/dL) Mean: 0.96\n- Creatinine (mg/dL) Median: 0.83\n- BUN (mg/dL) Mean: 17.3\n- BUN (mg/dL) Median: 11.3\n- WBC (K) Mean: 6.9\n- WBC (K) Median: 7.6\n- Platelets (K) Mean: 238\n- Platelets (K) Median: 223\n\n#### Non-Statin Subgroup\n- N: 125\n- ALT (U/L) Mean: 29.6\n- ALT (U/L) Median: 28.4\n- AST (U/L) Mean: 26.8\n- AST (U/L) Median: 25.8\n- Bilirubin (mg/dL) Mean: 0.84\n- Bilirubin (mg/dL) Median: 0.82\n- ALP (U/L) Mean: 59.9\n- ALP (U/L) Median: 61.5\n- Creatinine (mg/dL) Mean: 0.99\n- Creatinine (mg/dL) Median: 0.95\n- BUN (mg/dL) Mean: 13.4\n- BUN (mg/dL) Median: 14.2\n- WBC (K) Mean: 6.6\n- WBC (K) Median: 6.1\n- Platelets (K) Mean: 220\n- Platelets (K) Median: 212\n\n### Adverse Events\n- AE ID: AE-0025, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0026, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0027, Description: abdominal discomfort, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0028, Description: abdominal discomfort, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 55\n- ACE Inhibitor Count: 27\n- Metformin Count: 23\n- PPI Count: 17\n- NSAID Count: 12\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-021, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_08\n- PD ID: PD-022, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_10\n- PD ID: PD-023, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_05\n\n### Investigator Notes\n- Enrollment on track per protocol timeline\n- Subject retention rate within protocol targets\n\n### Events\n- Medical monitor weekly call completed\n- CRO quarterly oversight report submitted\n\n### Notes\n- Week 9: Statin subgroup hepatic panel shows ALT values at upper range. Non-statin subgroup stable. Routine operations continue.",
          "meta": {
            "episode_type": "signal",
            "phase": "early_signal",
            "signal_density": "low"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_010",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-06T10:00:00",
          "text": "## 2024-05-06 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 184\n- Active: 182\n- Screen Failures Cumulative: 20\n- Withdrawals Cumulative: 2\n\n#### Sites\n- Site 01 Enrolled: 18\n- Site 01 Active: 18\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 14\n- Site 02 Active: 14\n- Site 02 Statin Concomitant: 3\n- Site 03 Enrolled: 17\n- Site 03 Active: 17\n- Site 03 Statin Concomitant: 4\n- Site 04 Enrolled: 12\n- Site 04 Active: 12\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 15\n- Site 05 Active: 15\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 11\n- Site 06 Active: 11\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 20\n- Site 07 Active: 20\n- Site 07 Statin Concomitant: 5\n- Site 08 Enrolled: 14\n- Site 08 Active: 14\n- Site 08 Statin Concomitant: 3\n- Site 09 Enrolled: 15\n- Site 09 Active: 15\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 12\n- Site 10 Active: 12\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 17\n- Site 11 Active: 17\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 14\n- Site 12 Active: 14\n- Site 12 Statin Concomitant: 3\n\n### Lab Panels\n#### Statin Subgroup\n- N: 54\n- ALT (U/L) Mean: 37.2\n- ALT (U/L) Median: 35.2\n- AST (U/L) Mean: 32.1\n- AST (U/L) Median: 30.9\n- Bilirubin (mg/dL) Mean: 0.68\n- Bilirubin (mg/dL) Median: 0.65\n- ALP (U/L) Mean: 65.1\n- ALP (U/L) Median: 62.3\n- Creatinine (mg/dL) Mean: 1.09\n- Creatinine (mg/dL) Median: 0.88\n- BUN (mg/dL) Mean: 17.8\n- BUN (mg/dL) Median: 16.4\n- WBC (K/\u00b5L) Mean: 6.3\n- WBC (K/\u00b5L) Median: 6.7\n- Platelets (K/\u00b5L) Mean: 245\n- Platelets (K/\u00b5L) Median: 228\n\n#### Non-Statin Subgroup\n- N: 132\n- ALT (U/L) Mean: 23.2\n- ALT (U/L) Median: 22.4\n- AST (U/L) Mean: 27.8\n- AST (U/L) Median: 25.9\n- Bilirubin (mg/dL) Mean: 0.4\n- Bilirubin (mg/dL) Median: 0.39\n- ALP (U/L) Mean: 59.6\n- ALP (U/L) Median: 48.6\n- Creatinine (mg/dL) Mean: 0.81\n- Creatinine (mg/dL) Median: 0.98\n- BUN (mg/dL) Mean: 13.4\n- BUN (mg/dL) Median: 12.1\n- WBC (K/\u00b5L) Mean: 8.4\n- WBC (K/\u00b5L) Median: 7.1\n- Platelets (K/\u00b5L) Mean: 261\n- Platelets (K/\u00b5L) Median: 236\n\n### Adverse Events\n- AE ID: AE-0029, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0030, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0031, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0032, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 53\n- ACE Inhibitor Count: 30\n- Metformin Count: 24\n- PPI Count: 17\n- NSAID Count: 13\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-024, Description: Incorrect lab panel order, repeated, Severity: minor, Site: site_07\n\n### Investigator Notes\n- Training log updated for new study coordinator\n- Subject retention rate within protocol targets\n- Statin subgroup lab review: ALT mean 42 U/L, within 1.5x ULN; monitoring per protocol\n\n### Events\n- EDC system maintenance window: 2h downtime Saturday 02:00 UTC\n- IP resupply shipped to Sites 11, 12\n- Site 12 monitoring visit completed, 4 findings\n\n### Notes\n- Week 10: Statin subgroup hepatic panel shows ALT values at upper range. Non-statin subgroup stable. Routine operations continue.",
          "meta": {
            "episode_type": "signal",
            "phase": "early_signal",
            "signal_density": "low"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_011",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-13T10:00:00",
          "text": "## 2024-05-13 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 189\n- Active: 182\n- Screen Failures Cumulative: 27\n- Withdrawals Cumulative: 7\n\n#### Sites\n- Site 01\n  - Enrolled: 19\n  - Active: 19\n  - Statin Concomitant: 5\n- Site 02\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 3\n- Site 03\n  - Enrolled: 17\n  - Active: 17\n  - Statin Concomitant: 5\n- Site 04\n  - Enrolled: 12\n  - Active: 12\n  - Statin Concomitant: 3\n- Site 05\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 4\n- Site 06\n  - Enrolled: 11\n  - Active: 11\n  - Statin Concomitant: 3\n- Site 07\n  - Enrolled: 21\n  - Active: 21\n  - Statin Concomitant: 6\n- Site 08\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 3\n- Site 09\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 4\n- Site 10\n  - Enrolled: 12\n  - Active: 12\n  - Statin Concomitant: 3\n- Site 11\n  - Enrolled: 17\n  - Active: 17\n  - Statin Concomitant: 5\n- Site 12\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 55\n- ALT (U/L) Mean: 47.6\n- ALT (U/L) Median: 47.4\n- AST (U/L) Mean: 35.8\n- AST (U/L) Median: 34.3\n- Bilirubin (mg/dL) Mean: 0.7\n- Bilirubin (mg/dL) Median: 0.67\n- ALP (U/L) Mean: 67.5\n- ALP (U/L) Median: 61.8\n- Creatinine (mg/dL) Mean: 0.8\n- Creatinine (mg/dL) Median: 0.86\n- BUN (mg/dL) Mean: 13.5\n- BUN (mg/dL) Median: 15.1\n- WBC (K) Mean: 6.7\n- WBC (K) Median: 5.6\n- Platelets (K) Mean: 258\n- Platelets (K) Median: 256\n\n#### Non-Statin Subgroup\n- N: 132\n- ALT (U/L) Mean: 29.3\n- ALT (U/L) Median: 29.2\n- AST (U/L) Mean: 25.5\n- AST (U/L) Median: 25.2\n- Bilirubin (mg/dL) Mean: 0.46\n- Bilirubin (mg/dL) Median: 0.44\n- ALP (U/L) Mean: 53.2\n- ALP (U/L) Median: 50.8\n- Creatinine (mg/dL) Mean: 0.96\n- Creatinine (mg/dL) Median: 0.83\n- BUN (mg/dL) Mean: 17.5\n- BUN (mg/dL) Median: 11.1\n- WBC (K) Mean: 6.7\n- WBC (K) Median: 7.4\n- Platelets (K) Mean: 247\n- Platelets (K) Median: 232\n\n### Adverse Events\n- AE ID: AE-0033\n  - Description: nausea\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0034\n  - Description: insomnia\n  - Grade: 1\n  - Relatedness: unlikely related\n  - Resolved: true\n  - Subject Group: non_statin\n- AE ID: AE-0035\n  - Description: transaminase measurement out of range\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 51\n- ACE Inhibitor Count: 26\n- Metformin Count: 22\n- PPI Count: 17\n- NSAID Count: 12\n- Other Count: 34\n\n### Protocol Deviations\n- PD ID: PD-025\n  - Description: Concomitant medication not recorded at visit\n  - Severity: minor\n  - Site: site_01\n\n### Investigator Notes\n- Subject retention rate within protocol targets\n- EDC data entry backlog cleared, queries resolved\n\n### Events\n- Drug accountability audit at Site 04: no discrepancies\n- Site 09 pharmacy temperature log reviewed: compliant\n- Central lab courier pickup schedule adjusted for holiday\n\n### Notes\n- Week 11: Statin subgroup hepatic panel shows ALT values at upper range. Non-statin subgroup stable. Routine operations continue.",
          "meta": {
            "episode_type": "signal",
            "phase": "early_signal",
            "signal_density": "low"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_012",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-20T10:00:00",
          "text": "## 2024-05-20 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 192\n- Active: 186\n- Screen Failures Cumulative: 21\n- Withdrawals Cumulative: 6\n\n#### Sites\n- Site 01\n  - Enrolled: 19\n  - Active: 19\n  - Statin Concomitant: 5\n- Site 02\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 3\n- Site 03\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 04\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 3\n- Site 05\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 5\n- Site 06\n  - Enrolled: 11\n  - Active: 11\n  - Statin Concomitant: 3\n- Site 07\n  - Enrolled: 21\n  - Active: 21\n  - Statin Concomitant: 6\n- Site 08\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 4\n- Site 09\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 5\n- Site 10\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 4\n- Site 11\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 4\n- Site 12\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 4\n\n### Lab Panels\n- Statin Subgroup\n  - N: 51\n  - ALT (U/L) Mean: 47.2\n  - ALT (U/L) Median: 45.7\n  - AST (U/L) Mean: 41.0\n  - AST (U/L) Median: 41.0\n  - Bilirubin (mg/dL) Mean: 0.73\n  - Bilirubin (mg/dL) Median: 0.72\n  - ALP (U/L) Mean: 61.9\n  - ALP (U/L) Median: 56.0\n  - Creatinine (mg/dL) Mean: 1.07\n  - Creatinine (mg/dL) Median: 0.92\n  - BUN (mg/dL) Mean: 16.8\n  - BUN (mg/dL) Median: 15.4\n  - WBC (K) Mean: 7.7\n  - WBC (K) Median: 7.1\n  - Platelets (K) Mean: 257\n  - Platelets (K) Median: 250\n- Non-Statin Subgroup\n  - N: 123\n  - ALT (U/L) Mean: 22.0\n  - ALT (U/L) Median: 21.4\n  - AST (U/L) Mean: 23.5\n  - AST (U/L) Median: 22.1\n  - Bilirubin (mg/dL) Mean: 0.66\n  - Bilirubin (mg/dL) Median: 0.61\n  - ALP (U/L) Mean: 55.2\n  - ALP (U/L) Median: 61.9\n  - Creatinine (mg/dL) Mean: 1.06\n  - Creatinine (mg/dL) Median: 0.98\n  - BUN (mg/dL) Mean: 14.8\n  - BUN (mg/dL) Median: 12.3\n  - WBC (K) Mean: 6.7\n  - WBC (K) Median: 5.6\n  - Platelets (K) Mean: 234\n  - Platelets (K) Median: 221\n\n### Adverse Events\n- AE ID: AE-0036\n  - Description: insomnia\n  - Grade: 1\n  - Relatedness: unlikely related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0037\n  - Description: upper respiratory infection\n  - Grade: 1\n  - Relatedness: not related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0038\n  - Description: abdominal discomfort\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0039\n  - Description: transaminase measurement out of range\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 54\n- ACE Inhibitor Count: 30\n- Metformin Count: 23\n- PPI Count: 17\n- NSAID Count: 12\n- Other Count: 36\n\n### Protocol Deviations\n- PD ID: PD-026\n  - Description: Dose modification without documented PI approval\n  - Severity: moderate\n  - Site: site_07\n\n### Investigator Notes\n- Source document verification complete for prior monitoring visit\n- EDC data entry backlog cleared, queries resolved\n\n### Events\n- IVRS system update deployed, randomization unaffected\n- Bioanalytical lab shipment tracking confirmed for 2 samples\n- Site 03 new coordinator onboarding completed\n\n### Notes\n- Week 12: Statin subgroup hepatic panel shows ALT values at upper range. Non-statin subgroup stable. Routine operations continue.",
          "meta": {
            "episode_type": "signal",
            "phase": "early_signal",
            "signal_density": "low"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_013",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-05-27T10:00:00",
          "text": "## 2024-05-27 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 195\n- Active: 191\n- Screen Failures Cumulative: 29\n- Withdrawals Cumulative: 4\n\n#### Sites\n- Site 01\n  - Enrolled: 19\n  - Active: 19\n  - Statin Concomitant: 5\n- Site 02\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 4\n- Site 03\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 04\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 4\n- Site 05\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 4\n- Site 06\n  - Enrolled: 11\n  - Active: 11\n  - Statin Concomitant: 3\n- Site 07\n  - Enrolled: 21\n  - Active: 21\n  - Statin Concomitant: 6\n- Site 08\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 4\n- Site 09\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 5\n- Site 10\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 4\n- Site 11\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 12\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 52.4\n- ALT (U/L) Median: 50.8\n- AST (U/L) Mean: 45.0\n- AST (U/L) Median: 44.3\n- Bilirubin (mg/dL) Mean: 0.84\n- Bilirubin (mg/dL) Median: 0.82\n- ALP (U/L) Mean: 63.5\n- ALP (U/L) Median: 55.7\n- Creatinine (mg/dL) Mean: 0.83\n- Creatinine (mg/dL) Median: 0.85\n- BUN (mg/dL) Mean: 17.5\n- BUN (mg/dL) Median: 12.2\n- WBC (K) Mean: 8.4\n- WBC (K) Median: 5.7\n- Platelets (K) Mean: 238\n- Platelets (K) Median: 231\n\n#### Non-Statin Subgroup\n- N: 124\n- ALT (U/L) Mean: 20.7\n- ALT (U/L) Median: 20.4\n- AST (U/L) Mean: 18.1\n- AST (U/L) Median: 17.2\n- Bilirubin (mg/dL) Mean: 0.69\n- Bilirubin (mg/dL) Median: 0.66\n- ALP (U/L) Mean: 68.1\n- ALP (U/L) Median: 60.8\n- Creatinine (mg/dL) Mean: 0.84\n- Creatinine (mg/dL) Median: 0.88\n- BUN (mg/dL) Mean: 17.1\n- BUN (mg/dL) Median: 14.5\n- WBC (K) Mean: 8.5\n- WBC (K) Median: 5.6\n- Platelets (K) Mean: 218\n- Platelets (K) Median: 232\n\n### Adverse Events\n- AE ID: AE-0040, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0041, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0042, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0043, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0044, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 29\n- Metformin Count: 23\n- PPI Count: 18\n- NSAID Count: 12\n- Other Count: 38\n\n### Protocol Deviations\n- PD ID: PD-027, Description: Missed visit window (3 days late), Severity: minor, Site: site_01\n- PD ID: PD-028, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_08\n\n### Investigator Notes\n- Training log updated for new study coordinator\n- All CRFs current through prior visit cycle\n- Statin co-administered cohort ALT mean 58 U/L; values remain below 2x ULN action threshold\n\n### Events\n- IP resupply shipped to Sites 06, 02\n- Site 10 monitoring visit completed, 2 findings\n\n### Notes\n- Week 13: Statin subgroup hepatic panel shows ALT values at upper range. Non-statin subgroup stable. Routine operations continue.",
          "meta": {
            "episode_type": "signal",
            "phase": "early_signal",
            "signal_density": "low"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_014",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-03T10:00:00",
          "text": "## 2024-06-03 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 192\n- Active: 182\n- Screen Failures Cumulative: 28\n- Withdrawals Cumulative: 10\n\n#### Sites\n- Site 01 Enrolled: 19\n- Site 01 Active: 19\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 14\n- Site 02 Active: 14\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 18\n- Site 03 Active: 18\n- Site 03 Statin Concomitant: 4\n- Site 04 Enrolled: 13\n- Site 04 Active: 13\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 16\n- Site 05 Active: 16\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 11\n- Site 06 Active: 11\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 21\n- Site 07 Active: 21\n- Site 07 Statin Concomitant: 6\n- Site 08 Enrolled: 14\n- Site 08 Active: 14\n- Site 08 Statin Concomitant: 3\n- Site 09 Enrolled: 16\n- Site 09 Active: 16\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 13\n- Site 10 Active: 13\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 18\n- Site 11 Active: 18\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 14\n- Site 12 Active: 14\n- Site 12 Statin Concomitant: 3\n\n### Lab Panels\n#### Statin Subgroup\n- N: 53\n- ALT (U/L) Mean: 57.6\n- ALT (U/L) Median: 56.0\n- AST (U/L) Mean: 45.7\n- AST (U/L) Median: 45.7\n- Bilirubin (mg/dL) Mean: 0.86\n- Bilirubin (mg/dL) Median: 0.83\n- ALP (U/L) Mean: 65.4\n- ALP (U/L) Median: 57.0\n- Creatinine (mg/dL) Mean: 0.89\n- Creatinine (mg/dL) Median: 0.85\n- BUN (mg/dL) Mean: 14.7\n- BUN (mg/dL) Median: 13.1\n- WBC (K) Mean: 6.2\n- WBC (K) Median: 7.0\n- Platelets (K) Mean: 223\n- Platelets (K) Median: 223\n\n#### Non-Statin Subgroup\n- N: 124\n- ALT (U/L) Mean: 29.4\n- ALT (U/L) Median: 27.5\n- AST (U/L) Mean: 26.6\n- AST (U/L) Median: 25.1\n- Bilirubin (mg/dL) Mean: 0.43\n- Bilirubin (mg/dL) Median: 0.41\n- ALP (U/L) Mean: 74.1\n- ALP (U/L) Median: 70.2\n- Creatinine (mg/dL) Mean: 0.98\n- Creatinine (mg/dL) Median: 0.96\n- BUN (mg/dL) Mean: 17.8\n- BUN (mg/dL) Median: 12.4\n- WBC (K) Mean: 7.7\n- WBC (K) Median: 6.6\n- Platelets (K) Mean: 259\n- Platelets (K) Median: 226\n\n### Adverse Events\n- AE ID: AE-0045, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0046, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0047, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0048, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0049, Description: abdominal discomfort, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 55\n- ACE Inhibitor Count: 28\n- Metformin Count: 21\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 36\n\n### Protocol Deviations\n- PD ID: PD-029, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_06\n- PD ID: PD-030, Description: Lab sample mislabeled, corrected same day, Severity: minor, Site: site_02\n\n### Investigator Notes\n- Lab kits inventory adequate for next 4 weeks\n- Subject retention rate within protocol targets\n- EDC data entry backlog cleared, queries resolved\n\n### Events\n- CRO quarterly oversight report submitted\n- Medical monitor weekly call completed\n- Central lab courier pickup schedule adjusted for holiday\n- Site 07: ALT analyzer service notification, recalibration pending\n\n### Notes\n- Week 14: Site 07 ALT analyzer flagged for recalibration. Statin subgroup ALT values at 1.5-2x ULN.",
          "meta": {
            "episode_type": "signal",
            "phase": "early_signal",
            "signal_density": "low"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_015",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-10T10:00:00",
          "text": "## 2024-06-10 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 215\n- Active: 208\n- Screen Failures Cumulative: 33\n- Withdrawals Cumulative: 7\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 22\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 16\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 20\n- Site 03 Active: 20\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 14\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 18\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 12\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 23\n- Site 07 Active: 23\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 16\n- Site 08 Active: 16\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 14\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 20\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 16\n- Site 12 Active: 16\n- Site 12 Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 54\n- ALT (U/L) Mean: 62.2\n- ALT (U/L) Median: 61.3\n- AST (U/L) Mean: 51.0\n- AST (U/L) Median: 50.3\n- Bilirubin (mg/dL) Mean: 0.89\n- Bilirubin (mg/dL) Median: 0.86\n- ALP (U/L) Mean: 58.6\n- ALP (U/L) Median: 78.4\n- Creatinine (mg/dL) Mean: 0.97\n- Creatinine (mg/dL) Median: 0.8\n- BUN (mg/dL) Mean: 14.8\n- BUN (mg/dL) Median: 16.3\n- WBC (K) Mean: 6.4\n- WBC (K) Median: 7.9\n- Platelets (K) Mean: 241\n- Platelets (K) Median: 212\n\n#### Non-Statin Subgroup\n- N: 125\n- ALT (U/L) Mean: 26.0\n- ALT (U/L) Median: 25.2\n- AST (U/L) Mean: 22.2\n- AST (U/L) Median: 21.0\n- Bilirubin (mg/dL) Mean: 0.64\n- Bilirubin (mg/dL) Median: 0.59\n- ALP (U/L) Mean: 65.4\n- ALP (U/L) Median: 71.5\n- Creatinine (mg/dL) Mean: 0.86\n- Creatinine (mg/dL) Median: 0.86\n- BUN (mg/dL) Mean: 12.5\n- BUN (mg/dL) Median: 16.1\n- WBC (K) Mean: 5.9\n- WBC (K) Median: 6.9\n- Platelets (K) Mean: 229\n- Platelets (K) Median: 227\n\n### Adverse Events\n- AE ID: AE-0050, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0051, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0052, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0053, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0054, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 27\n- Metformin Count: 23\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-031, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_11\n\n### Investigator Notes\n- Study drug accountability reconciled, no discrepancies\n- Central lab results received within 48h turnaround\n- Site 07 ALT re-assay ordered for 8 specimens, calibration offset confirmed\n\n### Events\n- Drug accountability audit at Site 12: no discrepancies\n- IP resupply shipped to Sites 07, 03\n- Site 07 lab re-assay requested for 8 specimens flagged during calibration review\n\n### Notes\n- Week 15: Site 07 re-assay ordered. Statin subgroup hepatic values persist across sites.",
          "meta": {
            "episode_type": "signal",
            "phase": "early_signal",
            "signal_density": "low"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_016",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-17T10:00:00",
          "text": "## 2024-06-17 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 204\n- Active: 198\n- Screen Failures Cumulative: 47\n- Withdrawals Cumulative: 6\n\n#### Sites\n- Site 01\n  - Enrolled: 20\n  - Active: 20\n  - Statin Concomitant: 6\n- Site 02\n  - Enrolled: 15\n  - Active: 15\n  - Statin Concomitant: 4\n- Site 03\n  - Enrolled: 19\n  - Active: 19\n  - Statin Concomitant: 5\n- Site 04\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 4\n- Site 05\n  - Enrolled: 17\n  - Active: 17\n  - Statin Concomitant: 5\n- Site 06\n  - Enrolled: 12\n  - Active: 12\n  - Statin Concomitant: 3\n- Site 07\n  - Enrolled: 22\n  - Active: 22\n  - Statin Concomitant: 6\n- Site 08\n  - Enrolled: 15\n  - Active: 15\n  - Statin Concomitant: 3\n- Site 09\n  - Enrolled: 17\n  - Active: 17\n  - Statin Concomitant: 4\n- Site 10\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 4\n- Site 11\n  - Enrolled: 19\n  - Active: 19\n  - Statin Concomitant: 6\n- Site 12\n  - Enrolled: 15\n  - Active: 15\n  - Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 56\n- ALT (U/L) Mean: 76.2\n- ALT (U/L) Median: 75.3\n- AST (U/L) Mean: 59.0\n- AST (U/L) Median: 57.6\n- Bilirubin (mg/dL) Mean: 1.02\n- Bilirubin (mg/dL) Median: 0.99\n- ALP (U/L) Mean: 76.1\n- ALP (U/L) Median: 69.4\n- Creatinine (mg/dL) Mean: 0.99\n- Creatinine (mg/dL) Median: 0.83\n- BUN (mg/dL) Mean: 12.2\n- BUN (mg/dL) Median: 14.8\n- WBC (K) Mean: 7.0\n- WBC (K) Median: 6.4\n- Platelets (K) Mean: 233\n- Platelets (K) Median: 230\n\n#### Non-Statin Subgroup\n- N: 129\n- ALT (U/L) Mean: 24.7\n- ALT (U/L) Median: 22.8\n- AST (U/L) Mean: 21.9\n- AST (U/L) Median: 20.9\n- Bilirubin (mg/dL) Mean: 0.64\n- Bilirubin (mg/dL) Median: 0.62\n- ALP (U/L) Mean: 71.7\n- ALP (U/L) Median: 56.6\n- Creatinine (mg/dL) Mean: 0.93\n- Creatinine (mg/dL) Median: 0.89\n- BUN (mg/dL) Mean: 16.1\n- BUN (mg/dL) Median: 14.2\n- WBC (K) Mean: 7.1\n- WBC (K) Median: 7.4\n- Platelets (K) Mean: 245\n- Platelets (K) Median: 230\n\n### Adverse Events\n- AE ID: AE-0055, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0056, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0057, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0058, Description: nausea, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 51\n- ACE Inhibitor Count: 26\n- Metformin Count: 23\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-032, Description: Incorrect lab panel order, repeated, Severity: minor, Site: site_09\n- PD ID: PD-033, Description: Eligibility criterion reassessed, subject confirmed eligible, Severity: minor, Site: site_02\n- PD ID: PD-034, Description: Lab sample mislabeled, corrected same day, Severity: minor, Site: site_03\n\n### Investigator Notes\n- No new safety signals identified this week by local PI\n- Study drug accountability reconciled, no discrepancies\n- Regulatory binder audit: all documents current\n- Site 07 re-assay results: 6/8 specimens confirmed within 5% of original, 2 specimens offset by 12-15%\n\n### Events\n- Central lab courier pickup schedule adjusted for holiday\n- Medical monitor weekly call completed\n\n### Notes\n- Week 16: Site 07 re-assay complete; instrument offset confirmed for 2 of 8 specimens. Statin subgroup ALT approaching 2-3x ULN at multiple sites.",
          "meta": {
            "episode_type": "signal",
            "phase": "red_herring",
            "signal_density": "medium"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_017",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-06-24T10:00:00",
          "text": "## 2024-06-24 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 225\n- Active: 214\n- Screen Failures Cumulative: 30\n- Withdrawals Cumulative: 11\n\n#### Sites\n- Site 01 Enrolled: 23\n- Site 01 Active: 23\n- Site 01 Statin Concomitant: 7\n- Site 02 Enrolled: 17\n- Site 02 Active: 17\n- Site 02 Statin Concomitant: 5\n- Site 03 Enrolled: 21\n- Site 03 Active: 21\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 15\n- Site 04 Active: 15\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 19\n- Site 05 Active: 19\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 13\n- Site 06 Active: 13\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 24\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 17\n- Site 08 Active: 17\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 19\n- Site 09 Active: 19\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 15\n- Site 10 Active: 15\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 21\n- Site 11 Active: 21\n- Site 11 Statin Concomitant: 7\n- Site 12 Enrolled: 17\n- Site 12 Active: 17\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 53\n- ALT (U/L) Mean: 89.1\n- ALT (U/L) Median: 86.5\n- AST (U/L) Mean: 65.7\n- AST (U/L) Median: 63.9\n- Bilirubin (mg/dL) Mean: 1.13\n- Bilirubin (mg/dL) Median: 1.1\n- ALP (U/L) Mean: 80.0\n- ALP (U/L) Median: 75.0\n- Creatinine (mg/dL) Mean: 0.88\n- Creatinine (mg/dL) Median: 0.86\n- BUN (mg/dL) Mean: 16.0\n- BUN (mg/dL) Median: 16.5\n- WBC (K) Mean: 7.9\n- WBC (K) Median: 6.9\n- Platelets (K) Mean: 249\n- Platelets (K) Median: 243\n\n#### Non-Statin Subgroup\n- N: 130\n- ALT (U/L) Mean: 29.6\n- ALT (U/L) Median: 29.5\n- AST (U/L) Mean: 21.7\n- AST (U/L) Median: 20.8\n- Bilirubin (mg/dL) Mean: 0.46\n- Bilirubin (mg/dL) Median: 0.42\n- ALP (U/L) Mean: 68.4\n- ALP (U/L) Median: 62.2\n- Creatinine (mg/dL) Mean: 0.9\n- Creatinine (mg/dL) Median: 0.89\n- BUN (mg/dL) Mean: 15.7\n- BUN (mg/dL) Median: 15.3\n- WBC (K) Mean: 8.0\n- WBC (K) Median: 5.7\n- Platelets (K) Mean: 252\n- Platelets (K) Median: 230\n\n### Adverse Events\n- AE ID: AE-0059, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0060, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0061, Description: hepatic enzyme measurement out of range, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0062, Description: nausea, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0063, Description: abdominal pain, Grade: 2, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 54\n- ACE Inhibitor Count: 26\n- Metformin Count: 22\n- PPI Count: 18\n- NSAID Count: 13\n- Other Count: 34\n\n### Protocol Deviations\n- PD ID: PD-035, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_10\n- PD ID: PD-036, Description: Eligibility criterion reassessed, subject confirmed eligible, Severity: minor, Site: site_04\n\n### Investigator Notes\n- Lab kits inventory adequate for next 4 weeks\n- Enrollment on track per protocol timeline\n- Site pharmacy inventory verified\n\n### Events\n- Medical monitor weekly call completed\n- Central lab courier pickup schedule adjusted for holiday\n\n### Notes\n- Week 17: Statin subgroup hepatic enzymes 2-3x ULN across sites. SAE reports under review. Non-statin subgroup within range.",
          "meta": {
            "episode_type": "signal",
            "phase": "escalation",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_018",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-01T10:00:00",
          "text": "## 2024-07-01 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 210\n- Active: 204\n- Screen Failures Cumulative: 53\n- Withdrawals Cumulative: 6\n\n#### Sites\n- Site 01 Enrolled: 21\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 7\n- Site 02 Enrolled: 16\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 19\n- Site 03 Active: 19\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 14\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 17\n- Site 05 Active: 17\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 12\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 4\n- Site 07 Enrolled: 23\n- Site 07 Active: 23\n- Site 07 Statin Concomitant: 6\n- Site 08 Enrolled: 16\n- Site 08 Active: 16\n- Site 08 Statin Concomitant: 5\n- Site 09 Enrolled: 17\n- Site 09 Active: 17\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 14\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 19\n- Site 11 Active: 19\n- Site 11 Statin Concomitant: 4\n- Site 12 Enrolled: 16\n- Site 12 Active: 16\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n- Statin Subgroup N: 53\n- Statin Subgroup ALT Mean (U/L): 90.2\n- Statin Subgroup ALT Median (U/L): 88.7\n- Statin Subgroup AST Mean (U/L): 69.2\n- Statin Subgroup AST Median (U/L): 69.1\n- Statin Subgroup Bilirubin Mean (mg/dL): 1.44\n- Statin Subgroup Bilirubin Median (mg/dL): 1.43\n- Statin Subgroup ALP Mean (U/L): 83.4\n- Statin Subgroup ALP Median (U/L): 76.7\n- Statin Subgroup Creatinine Mean (mg/dL): 0.85\n- Statin Subgroup Creatinine Median (mg/dL): 0.87\n- Statin Subgroup BUN Mean (mg/dL): 17.2\n- Statin Subgroup BUN Median (mg/dL): 14.6\n- Statin Subgroup WBC Mean (K/uL): 6.8\n- Statin Subgroup WBC Median (K/uL): 7.6\n- Statin Subgroup Platelets Mean (K/uL): 225\n- Statin Subgroup Platelets Median (K/uL): 215\n- Non-Statin Subgroup N: 120\n- Non-Statin Subgroup ALT Mean (U/L): 25.7\n- Non-Statin Subgroup ALT Median (U/L): 23.9\n- Non-Statin Subgroup AST Mean (U/L): 18.7\n- Non-Statin Subgroup AST Median (U/L): 17.5\n- Non-Statin Subgroup Bilirubin Mean (mg/dL): 0.64\n- Non-Statin Subgroup Bilirubin Median (mg/dL): 0.64\n- Non-Statin Subgroup ALP Mean (U/L): 52.5\n- Non-Statin Subgroup ALP Median (U/L): 54.2\n- Non-Statin Subgroup Creatinine Mean (mg/dL): 0.87\n- Non-Statin Subgroup Creatinine Median (mg/dL): 0.95\n- Non-Statin Subgroup BUN Mean (mg/dL): 17.1\n- Non-Statin Subgroup BUN Median (mg/dL): 16.5\n- Non-Statin Subgroup WBC Mean (K/uL): 6.6\n- Non-Statin Subgroup WBC Median (K/uL): 6.9\n- Non-Statin Subgroup Platelets Mean (K/uL): 256\n- Non-Statin Subgroup Platelets Median (K/uL): 255\n\n### Adverse Events\n- AE ID: AE-0064, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0065, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0066, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0067, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0068, Description: abdominal pain, Grade: 2, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0069, Description: fatigue, Grade: 2, Relatedness: possibly related, Resolved: false, Subject Group: statin\n- AE ID: AE-0070, Description: Hy's Law case: ALT 4.2x ULN, total bilirubin 2.8x ULN, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 53\n- ACE Inhibitor Count: 26\n- Metformin Count: 23\n- PPI Count: 19\n- NSAID Count: 13\n- Other Count: 38\n\n### Protocol Deviations\n- PD ID: PD-037, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_06\n- PD ID: PD-038, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_10\n- PD ID: PD-039, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_10\n\n### Investigator Notes\n- Central lab results received within 48h turnaround\n- Source document verification complete for prior monitoring visit\n- Site pharmacy inventory verified\n- SAE report filed: subject 07-118, statin subgroup, ALT 4.2x ULN with bilirubin 2.8x ULN\n- Statin subgroup hepatic panel mean ALT 95 U/L across 8 sites\n\n### Events\n- Data management plan revision v2.5 distributed\n- Data management plan revision v2.2 distributed\n- Site 08 monitoring visit completed, 3 findings\n- SAE report submitted to sponsor safety group within 24h\n\n### Notes\n- Week 18: Statin subgroup hepatic enzymes 2-3x ULN across sites. SAE reports under review. Non-statin subgroup within range.",
          "meta": {
            "episode_type": "signal",
            "phase": "escalation",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_019",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-08T10:00:00",
          "text": "## 2024-07-08 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 202\n- Active: 196\n- Screen Failures Cumulative: 37\n- Withdrawals Cumulative: 6\n\n### Sites\n- Site 01\n  - Enrolled: 20\n  - Active: 20\n  - Statin Concomitant: 6\n- Site 02\n  - Enrolled: 15\n  - Active: 15\n  - Statin Concomitant: 3\n- Site 03\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 04\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 3\n- Site 05\n  - Enrolled: 17\n  - Active: 17\n  - Statin Concomitant: 5\n- Site 06\n  - Enrolled: 12\n  - Active: 12\n  - Statin Concomitant: 3\n- Site 07\n  - Enrolled: 22\n  - Active: 22\n  - Statin Concomitant: 7\n- Site 08\n  - Enrolled: 15\n  - Active: 15\n  - Statin Concomitant: 4\n- Site 09\n  - Enrolled: 17\n  - Active: 17\n  - Statin Concomitant: 4\n- Site 10\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 3\n- Site 11\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 12\n  - Enrolled: 15\n  - Active: 15\n  - Statin Concomitant: 5\n\n### Lab Panels\n- Statin Subgroup\n  - N: 54\n  - ALT (U/L) Mean: 103.2\n  - ALT (U/L) Median: 100.3\n  - AST (U/L) Mean: 73.7\n  - AST (U/L) Median: 73.6\n  - Bilirubin (mg/dL) Mean: 1.56\n  - Bilirubin (mg/dL) Median: 1.53\n  - ALP (U/L) Mean: 74.1\n  - ALP (U/L) Median: 69.1\n  - Creatinine (mg/dL) Mean: 0.82\n  - Creatinine (mg/dL) Median: 0.95\n  - BUN (mg/dL) Mean: 13.4\n  - BUN (mg/dL) Median: 13.0\n  - WBC (K) Mean: 7.8\n  - WBC (K) Median: 5.9\n  - Platelets (K) Mean: 262\n  - Platelets (K) Median: 233\n- Non-Statin Subgroup\n  - N: 120\n  - ALT (U/L) Mean: 24.5\n  - ALT (U/L) Median: 23.8\n  - AST (U/L) Mean: 23.2\n  - AST (U/L) Median: 22.3\n  - Bilirubin (mg/dL) Mean: 0.64\n  - Bilirubin (mg/dL) Median: 0.62\n  - ALP (U/L) Mean: 50.8\n  - ALP (U/L) Median: 56.3\n  - Creatinine (mg/dL) Mean: 1.04\n  - Creatinine (mg/dL) Median: 0.95\n  - BUN (mg/dL) Mean: 15.2\n  - BUN (mg/dL) Median: 12.9\n  - WBC (K) Mean: 5.7\n  - WBC (K) Median: 7.1\n  - Platelets (K) Mean: 242\n  - Platelets (K) Median: 227\n\n### Adverse Events\n- AE ID: AE-0071\n  - Description: insomnia\n  - Grade: 1\n  - Relatedness: unlikely related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0072\n  - Description: headache\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0073\n  - Description: fatigue\n  - Grade: 2\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0074\n  - Description: fatigue\n  - Grade: 2\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 28\n- Metformin Count: 21\n- PPI Count: 18\n- NSAID Count: 11\n- Other Count: 36\n\n### Protocol Deviations\n- PD ID: PD-040\n  - Description: IP temperature excursion during shipment, 2h out of range\n  - Severity: moderate\n  - Site: site_08\n- PD ID: PD-041\n  - Description: Concomitant medication not recorded at visit\n  - Severity: minor\n  - Site: site_07\n\n### Investigator Notes\n- Training log updated for new study coordinator\n- EDC data entry backlog cleared, queries resolved\n- Cross-site review: statin subgroup ALT out of range at Sites 01, 03, 05, 07, 09, 11; non-statin subgroup within reference range at all sites\n\n### Events\n- Drug accountability audit at Site 04: no discrepancies\n- IVRS system update deployed, randomization unaffected\n- Medical monitor weekly call completed\n\n### Notes\n- Week 19: Statin subgroup hepatic enzymes 2-3x ULN across sites. SAE reports under review. Non-statin subgroup within range.",
          "meta": {
            "episode_type": "signal",
            "phase": "escalation",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_020",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-15T10:00:00",
          "text": "## 2024-07-15 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 216\n- Active: 206\n- Screen Failures Cumulative: 45\n- Withdrawals Cumulative: 10\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 22\n- Site 01 Statin Concomitant: 7\n- Site 02 Enrolled: 16\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 5\n- Site 03 Enrolled: 20\n- Site 03 Active: 20\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 14\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 18\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 4\n- Site 06 Enrolled: 12\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 24\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 6\n- Site 08 Enrolled: 16\n- Site 08 Active: 16\n- Site 08 Statin Concomitant: 5\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 14\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 20\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 16\n- Site 12 Active: 16\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 54\n- ALT (U/L) Mean: 103.2\n- ALT (U/L) Median: 102.1\n- AST (U/L) Mean: 82.6\n- AST (U/L) Median: 81.2\n- Bilirubin (mg/dL) Mean: 1.87\n- Bilirubin (mg/dL) Median: 1.85\n- ALP (U/L) Mean: 79.2\n- ALP (U/L) Median: 55.7\n- Creatinine (mg/dL) Mean: 0.99\n- Creatinine (mg/dL) Median: 1.0\n- BUN (mg/dL) Mean: 16.9\n- BUN (mg/dL) Median: 12.8\n- WBC (K) Mean: 6.2\n- WBC (K) Median: 6.1\n- Platelets (K) Mean: 219\n- Platelets (K) Median: 257\n\n#### Non-Statin Subgroup\n- N: 123\n- ALT (U/L) Mean: 21.8\n- ALT (U/L) Median: 20.2\n- AST (U/L) Mean: 18.5\n- AST (U/L) Median: 16.6\n- Bilirubin (mg/dL) Mean: 0.67\n- Bilirubin (mg/dL) Median: 0.66\n- ALP (U/L) Mean: 64.9\n- ALP (U/L) Median: 53.5\n- Creatinine (mg/dL) Mean: 1.03\n- Creatinine (mg/dL) Median: 0.97\n- BUN (mg/dL) Mean: 13.2\n- BUN (mg/dL) Median: 12.7\n- WBC (K) Mean: 8.5\n- WBC (K) Median: 7.6\n- Platelets (K) Mean: 257\n- Platelets (K) Median: 227\n\n### Adverse Events\n- AE ID: AE-0075, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0076, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0077, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0078, Description: hepatic enzyme measurement out of range, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0079, Description: Hy's Law case: ALT 3.8x ULN, total bilirubin 2.3x ULN, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 55\n- ACE Inhibitor Count: 28\n- Metformin Count: 21\n- PPI Count: 17\n- NSAID Count: 12\n- Other Count: 33\n\n### Protocol Deviations\n- PD ID: PD-042, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_07\n- PD ID: PD-043, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_06\n\n### Investigator Notes\n- Central lab results received within 48h turnaround\n- Lab kits inventory adequate for next 4 weeks\n- SAE report filed: subject 03-042, statin subgroup, ALT 3.8x ULN with bilirubin 2.3x ULN\n- Pharmacology consult requested: CYP3A4 inhibition profile of LNS-4821 under review\n\n### Events\n- Site 07 monitoring visit completed, 3 findings\n- Bioanalytical lab shipment tracking confirmed for 1 samples\n- Central lab courier pickup schedule adjusted for holiday\n- SAE report submitted to sponsor safety group and regulatory authority\n\n### Notes\n- Week 20: Cross-site statin subgroup hepatic signal confirmed. DDI pharmacology review in progress.",
          "meta": {
            "episode_type": "signal",
            "phase": "escalation",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_021",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-22T10:00:00",
          "text": "## 2024-07-22 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 219\n- Active: 209\n- Screen Failures Cumulative: 35\n- Withdrawals Cumulative: 10\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 22\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 16\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 20\n- Site 03 Active: 20\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 14\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 18\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 13\n- Site 06 Active: 13\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 24\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 6\n- Site 08 Enrolled: 16\n- Site 08 Active: 16\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 14\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 20\n- Site 11 Statin Concomitant: 6\n- Site 12 Enrolled: 16\n- Site 12 Active: 16\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 54\n- ALT (U/L) Mean: 111.7\n- ALT (U/L) Median: 110.7\n- AST (U/L) Mean: 86.1\n- AST (U/L) Median: 84.4\n- Bilirubin (mg/dL) Mean: 1.91\n- Bilirubin (mg/dL) Median: 1.9\n- ALP (U/L) Mean: 84.1\n- ALP (U/L) Median: 61.6\n- Creatinine (mg/dL) Mean: 1.06\n- Creatinine (mg/dL) Median: 0.95\n- BUN (mg/dL) Mean: 15.3\n- BUN (mg/dL) Median: 15.5\n- WBC (K) Mean: 6.9\n- WBC (K) Median: 7.1\n- Platelets (K) Mean: 239\n- Platelets (K) Median: 236\n\n#### Non-Statin Subgroup\n- N: 120\n- ALT (U/L) Mean: 25.8\n- ALT (U/L) Median: 24.8\n- AST (U/L) Mean: 28.8\n- AST (U/L) Median: 27.5\n- Bilirubin (mg/dL) Mean: 0.71\n- Bilirubin (mg/dL) Median: 0.71\n- ALP (U/L) Mean: 57.8\n- ALP (U/L) Median: 48.6\n- Creatinine (mg/dL) Mean: 0.87\n- Creatinine (mg/dL) Median: 0.84\n- BUN (mg/dL) Mean: 16.8\n- BUN (mg/dL) Median: 15.3\n- WBC (K) Mean: 8.4\n- WBC (K) Median: 6.0\n- Platelets (K) Mean: 225\n- Platelets (K) Median: 253\n\n### Adverse Events\n- AE ID: AE-0080, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0081, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0082, Description: nausea, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0083, Description: fatigue, Grade: 2, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 56\n- ACE Inhibitor Count: 29\n- Metformin Count: 23\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 36\n\n### Protocol Deviations\n- PD ID: PD-044, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_03\n- PD ID: PD-045, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_10\n\n### Investigator Notes\n- No new safety signals identified this week by local PI\n- Study drug accountability reconciled, no discrepancies\n- Multi-site pattern confirmed: ALT out of range in statin co-administered patients independent of site\n\n### Events\n- IVRS system update deployed, randomization unaffected\n- Regulatory submission packet sent to Site 08\n\n### Notes\n- Week 21: Cross-site statin subgroup hepatic signal confirmed. DDI pharmacology review in progress.",
          "meta": {
            "episode_type": "signal",
            "phase": "escalation",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_022",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-07-29T10:00:00",
          "text": "## 2024-07-29 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 236\n- Active: 230\n- Screen Failures Cumulative: 50\n- Withdrawals Cumulative: 6\n\n#### Sites\n- Site 01\n  - Enrolled: 24\n  - Active: 24\n  - Statin Concomitant: 7\n- Site 02\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 03\n  - Enrolled: 22\n  - Active: 22\n  - Statin Concomitant: 7\n- Site 04\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 4\n- Site 05\n  - Enrolled: 20\n  - Active: 20\n  - Statin Concomitant: 6\n- Site 06\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 3\n- Site 07\n  - Enrolled: 26\n  - Active: 26\n  - Statin Concomitant: 6\n- Site 08\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 4\n- Site 09\n  - Enrolled: 20\n  - Active: 20\n  - Statin Concomitant: 6\n- Site 10\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 4\n- Site 11\n  - Enrolled: 22\n  - Active: 22\n  - Statin Concomitant: 7\n- Site 12\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 123.1\n- ALT (U/L) Median: 121.0\n- AST (U/L) Mean: 89.3\n- AST (U/L) Median: 88.8\n- Bilirubin (mg/dL) Mean: 2.2\n- Bilirubin (mg/dL) Median: 2.2\n- ALP (U/L) Mean: 77.8\n- ALP (U/L) Median: 67.6\n- Creatinine (mg/dL) Mean: 0.97\n- Creatinine (mg/dL) Median: 0.88\n- BUN (mg/dL) Mean: 13.8\n- BUN (mg/dL) Median: 11.6\n- WBC (K) Mean: 7.7\n- WBC (K) Median: 6.7\n- Platelets (K) Mean: 261\n- Platelets (K) Median: 243\n\n#### Non-Statin Subgroup\n- N: 129\n- ALT (U/L) Mean: 28.6\n- ALT (U/L) Median: 27.4\n- AST (U/L) Mean: 30.0\n- AST (U/L) Median: 29.0\n- Bilirubin (mg/dL) Mean: 0.53\n- Bilirubin (mg/dL) Median: 0.51\n- ALP (U/L) Mean: 54.6\n- ALP (U/L) Median: 58.8\n- Creatinine (mg/dL) Mean: 1.1\n- Creatinine (mg/dL) Median: 0.9\n- BUN (mg/dL) Mean: 17.2\n- BUN (mg/dL) Median: 12.5\n- WBC (K) Mean: 7.1\n- WBC (K) Median: 6.6\n- Platelets (K) Mean: 247\n- Platelets (K) Median: 227\n\n### Adverse Events\n- AE ID: AE-0084, Description: headache, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0085, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0086, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0087, Description: hepatic enzyme measurement out of range, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0088, Description: hepatic enzyme measurement out of range, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 53\n- ACE Inhibitor Count: 30\n- Metformin Count: 24\n- PPI Count: 17\n- NSAID Count: 13\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-046, Description: Lab sample mislabeled, corrected same day, Severity: minor, Site: site_10\n\n### Investigator Notes\n- Central lab results received within 48h turnaround\n- All SAE narratives submitted within reporting window\n- IEC/IRB annual renewal submitted on schedule\n\n### Events\n- Site 09 new coordinator onboarding completed\n- Regulatory submission packet sent to Site 11\n- Site 01 new coordinator onboarding completed\n\n### Notes\n- Week 22: Cross-site statin subgroup hepatic signal confirmed. DDI pharmacology review in progress.",
          "meta": {
            "episode_type": "signal",
            "phase": "escalation",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_023",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-05T10:00:00",
          "text": "## 2024-08-05 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 210\n- Active: 196\n- Screen Failures Cumulative: 58\n- Withdrawals Cumulative: 14\n\n### Sites\n- Site 01 Enrolled: 21\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 7\n- Site 02 Enrolled: 16\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 19\n- Site 03 Active: 19\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 14\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 17\n- Site 05 Active: 17\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 12\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 23\n- Site 07 Active: 22\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 16\n- Site 08 Active: 15\n- Site 08 Statin Concomitant: 5\n- Site 09 Enrolled: 17\n- Site 09 Active: 17\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 14\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 19\n- Site 11 Active: 18\n- Site 11 Statin Concomitant: 4\n- Site 12 Enrolled: 16\n- Site 12 Active: 15\n- Site 12 Statin Concomitant: 4\n\n### Lab Panels\n- Statin Subgroup N: 52\n- Statin Subgroup ALT (U/L) Mean: 127.9\n- Statin Subgroup ALT (U/L) Median: 125.2\n- Statin Subgroup AST (U/L) Mean: 91.5\n- Statin Subgroup AST (U/L) Median: 91.0\n- Statin Subgroup Bilirubin (mg/dL) Mean: 1.92\n- Statin Subgroup Bilirubin (mg/dL) Median: 1.9\n- Statin Subgroup ALP (U/L) Mean: 64.0\n- Statin Subgroup ALP (U/L) Median: 73.5\n- Statin Subgroup Creatinine (mg/dL) Mean: 0.95\n- Statin Subgroup Creatinine (mg/dL) Median: 0.91\n- Statin Subgroup BUN (mg/dL) Mean: 13.8\n- Statin Subgroup BUN (mg/dL) Median: 11.3\n- Statin Subgroup WBC (K) Mean: 6.7\n- Statin Subgroup WBC (K) Median: 6.4\n- Statin Subgroup Platelets (K) Mean: 257\n- Statin Subgroup Platelets (K) Median: 235\n- Non-Statin Subgroup N: 127\n- Non-Statin Subgroup ALT (U/L) Mean: 27.9\n- Non-Statin Subgroup ALT (U/L) Median: 27.8\n- Non-Statin Subgroup AST (U/L) Mean: 27.3\n- Non-Statin Subgroup AST (U/L) Median: 26.0\n- Non-Statin Subgroup Bilirubin (mg/dL) Mean: 0.51\n- Non-Statin Subgroup Bilirubin (mg/dL) Median: 0.49\n- Non-Statin Subgroup ALP (U/L) Mean: 61.8\n- Non-Statin Subgroup ALP (U/L) Median: 54.5\n- Non-Statin Subgroup Creatinine (mg/dL) Mean: 0.94\n- Non-Statin Subgroup Creatinine (mg/dL) Median: 0.81\n- Non-Statin Subgroup BUN (mg/dL) Mean: 16.2\n- Non-Statin Subgroup BUN (mg/dL) Median: 14.7\n- Non-Statin Subgroup WBC (K) Mean: 7.7\n- Non-Statin Subgroup WBC (K) Median: 7.0\n- Non-Statin Subgroup Platelets (K) Mean: 231\n- Non-Statin Subgroup Platelets (K) Median: 214\n\n### Adverse Events\n- AE ID: AE-0089, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0090, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0091, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0092, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0093, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0094, Description: drug-induced liver injury, Grade: 3, Relatedness: definitely related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 55\n- ACE Inhibitor Count: 29\n- Metformin Count: 21\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 32\n\n### Protocol Deviations\n- PD ID: PD-047, Description: Missed visit window (2 days late), Severity: minor, Site: site_11\n\n### Investigator Notes\n- Training log updated for new study coordinator\n- Lab kits inventory adequate for next 4 weeks\n- No new safety signals identified this week by local PI\n- PK sub-study interim: LNS-4821 plasma concentration data consistent with CYP3A4 inhibition; atorvastatin AUC 3.2x in co-administered subjects\n\n### Events\n- CRO quarterly oversight report submitted\n- Drug accountability audit at Site 04: no discrepancies\n- PK sub-study interim data package distributed to DSMB members\n\n### Notes\n- Week 23: PK data supports CYP3A4 inhibition mechanism. Statin subgroup ALT 3-4x ULN.",
          "meta": {
            "episode_type": "signal",
            "phase": "root_cause",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_024",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-12T10:00:00",
          "text": "## 2024-08-12 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 244\n- Active: 236\n- Screen Failures Cumulative: 49\n- Withdrawals Cumulative: 8\n\n### Sites\n- Site 01\n  - Enrolled: 25\n  - Active: 25\n  - Statin Concomitant: 6\n- Site 02\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 03\n  - Enrolled: 22\n  - Active: 22\n  - Statin Concomitant: 7\n- Site 04\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 5\n- Site 05\n  - Enrolled: 20\n  - Active: 20\n  - Statin Concomitant: 5\n- Site 06\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 4\n- Site 07\n  - Enrolled: 27\n  - Active: 27\n  - Statin Concomitant: 8\n- Site 08\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 09\n  - Enrolled: 20\n  - Active: 20\n  - Statin Concomitant: 6\n- Site 10\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 4\n- Site 11\n  - Enrolled: 22\n  - Active: 22\n  - Statin Concomitant: 5\n- Site 12\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n\n### Lab Panels\n- Statin Subgroup\n  - N: 53\n  - ALT (U/L) Mean: 133.5\n  - ALT (U/L) Median: 131.2\n  - AST (U/L) Mean: 98.1\n  - AST (U/L) Median: 96.3\n  - Bilirubin (mg/dL) Mean: 2.08\n  - Bilirubin (mg/dL) Median: 2.05\n  - ALP (U/L) Mean: 71.4\n  - ALP (U/L) Median: 70.4\n  - Creatinine (mg/dL) Mean: 0.97\n  - Creatinine (mg/dL) Median: 0.9\n  - BUN (mg/dL) Mean: 16.8\n  - BUN (mg/dL) Median: 16.2\n  - WBC (K) Mean: 6.9\n  - WBC (K) Median: 7.4\n  - Platelets (K) Mean: 253\n  - Platelets (K) Median: 237\n- Non-Statin Subgroup\n  - N: 120\n  - ALT (U/L) Mean: 21.8\n  - ALT (U/L) Median: 20.0\n  - AST (U/L) Mean: 19.6\n  - AST (U/L) Median: 18.7\n  - Bilirubin (mg/dL) Mean: 0.79\n  - Bilirubin (mg/dL) Median: 0.74\n  - ALP (U/L) Mean: 52.3\n  - ALP (U/L) Median: 69.0\n  - Creatinine (mg/dL) Mean: 0.94\n  - Creatinine (mg/dL) Median: 0.84\n  - BUN (mg/dL) Mean: 15.3\n  - BUN (mg/dL) Median: 12.6\n  - WBC (K) Mean: 8.0\n  - WBC (K) Median: 7.6\n  - Platelets (K) Mean: 248\n  - Platelets (K) Median: 246\n\n### Adverse Events\n- AE ID: AE-0095\n  - Description: upper respiratory infection\n  - Grade: 1\n  - Relatedness: not related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0096\n  - Description: fatigue\n  - Grade: 1\n  - Relatedness: unlikely related\n  - Resolved: true\n  - Subject Group: statin\n- AE ID: AE-0097\n  - Description: nausea\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: non_statin\n- AE ID: AE-0098\n  - Description: headache\n  - Grade: 1\n  - Relatedness: possibly related\n  - Resolved: true\n  - Subject Group: non_statin\n- AE ID: AE-0099\n  - Description: hepatocellular injury\n  - Grade: 3\n  - Relatedness: probably related\n  - Resolved: false\n  - Subject Group: statin\n- AE ID: AE-0100\n  - Description: jaundice\n  - Grade: 2\n  - Relatedness: probably related\n  - Resolved: true\n  - Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 55\n- ACE Inhibitor Count: 27\n- Metformin Count: 22\n- PPI Count: 18\n- NSAID Count: 13\n- Other Count: 38\n\n### Protocol Deviations\n- PD ID: PD-048\n  - Description: Eligibility criterion reassessed, subject confirmed eligible\n  - Severity: minor\n  - Site: site_11\n- PD ID: PD-049\n  - Description: Lab sample mislabeled, corrected same day\n  - Severity: minor\n  - Site: site_08\n\n### Investigator Notes\n- IEC/IRB annual renewal submitted on schedule\n- Central lab results received within 48h turnaround\n- Query resolution rate at 94%\n- DSMB teleconference scheduled; cross-site statin subgroup hepatic data package compiled\n\n### Events\n- CRO quarterly oversight report submitted\n- IVRS system update deployed, randomization unaffected\n- DSMB meeting materials finalized and transmitted\n\n### Notes\n- Week 24: DSMB review pending. Statin subgroup hepatic data compiled across all sites.",
          "meta": {
            "episode_type": "signal",
            "phase": "root_cause",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_025",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-19T10:00:00",
          "text": "## 2024-08-19 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 231\n- Active: 216\n- Screen Failures Cumulative: 42\n- Withdrawals Cumulative: 15\n\n#### Sites\n- Site 01 Enrolled: 23\n- Site 01 Active: 22\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 17\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 5\n- Site 03 Enrolled: 21\n- Site 03 Active: 21\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 15\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 5\n- Site 05 Enrolled: 19\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 4\n- Site 06 Enrolled: 13\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 25\n- Site 07 Active: 25\n- Site 07 Statin Concomitant: 8\n- Site 08 Enrolled: 17\n- Site 08 Active: 17\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 19\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 6\n- Site 10 Enrolled: 15\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 21\n- Site 11 Active: 20\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 17\n- Site 12 Active: 17\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 56\n- ALT (U/L) Mean: 152.0\n- ALT (U/L) Median: 150.5\n- AST (U/L) Mean: 98.1\n- AST (U/L) Median: 97.3\n- Bilirubin (mg/dL) Mean: 2.41\n- Bilirubin (mg/dL) Median: 2.41\n- ALP (U/L) Mean: 63.2\n- ALP (U/L) Median: 66.9\n- Creatinine (mg/dL) Mean: 1.09\n- Creatinine (mg/dL) Median: 0.85\n- BUN (mg/dL) Mean: 12.9\n- BUN (mg/dL) Median: 11.7\n- WBC (K) Mean: 7.5\n- WBC (K) Median: 7.2\n- Platelets (K) Mean: 241\n- Platelets (K) Median: 246\n\n#### Non-Statin Subgroup\n- N: 122\n- ALT (U/L) Mean: 21.7\n- ALT (U/L) Median: 21.0\n- AST (U/L) Mean: 25.6\n- AST (U/L) Median: 23.7\n- Bilirubin (mg/dL) Mean: 0.89\n- Bilirubin (mg/dL) Median: 0.87\n- ALP (U/L) Mean: 67.1\n- ALP (U/L) Median: 59.1\n- Creatinine (mg/dL) Mean: 0.89\n- Creatinine (mg/dL) Median: 0.96\n- BUN (mg/dL) Mean: 17.3\n- BUN (mg/dL) Median: 14.8\n- WBC (K) Mean: 8.0\n- WBC (K) Median: 6.2\n- Platelets (K) Mean: 251\n- Platelets (K) Median: 243\n\n### Adverse Events\n- AE ID: AE-0101, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0102, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0103, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0104, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0105, Description: drug-induced liver injury, Grade: 3, Relatedness: definitely related, Resolved: false, Subject Group: statin\n- AE ID: AE-0106, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 28\n- Metformin Count: 22\n- PPI Count: 18\n- NSAID Count: 11\n- Other Count: 38\n\n### Protocol Deviations\n- PD ID: PD-050, Description: Eligibility criterion reassessed, subject confirmed eligible, Severity: minor, Site: site_02\n- PD ID: PD-051, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_10\n- PD ID: PD-052, Description: Missed visit window (4 days late), Severity: minor, Site: site_01\n\n### Investigator Notes\n- Query resolution rate at 94%\n- All CRFs current through prior visit cycle\n- DDI mechanism confirmed: LNS-4821 CYP3A4 inhibition leads to statin accumulation; protocol amendment drafted to exclude statin co-administration\n\n### Events\n- Site 01 new coordinator onboarding completed\n- Data management plan revision v2.5 distributed\n- CRO quarterly oversight report submitted\n- Protocol amendment v4.0 drafted; sponsor medical review initiated\n\n### Notes\n- Week 25: DDI confirmed. Protocol amendment drafted to exclude statin co-administration.",
          "meta": {
            "episode_type": "signal",
            "phase": "root_cause",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_026",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-08-26T10:00:00",
          "text": "## 2024-08-26 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 234\n- Active: 220\n- Screen Failures Cumulative: 69\n- Withdrawals Cumulative: 14\n\n#### Sites\n- Site 01 Enrolled: 24\n- Site 01 Active: 23\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 17\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 5\n- Site 03 Enrolled: 22\n- Site 03 Active: 21\n- Site 03 Statin Concomitant: 7\n- Site 04 Enrolled: 16\n- Site 04 Active: 15\n- Site 04 Statin Concomitant: 5\n- Site 05 Enrolled: 19\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 6\n- Site 06 Enrolled: 13\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 25\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 8\n- Site 08 Enrolled: 17\n- Site 08 Active: 17\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 19\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 16\n- Site 10 Active: 16\n- Site 10 Statin Concomitant: 5\n- Site 11 Enrolled: 22\n- Site 11 Active: 21\n- Site 11 Statin Concomitant: 6\n- Site 12 Enrolled: 17\n- Site 12 Active: 16\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 148.8\n- ALT (U/L) Median: 148.6\n- AST (U/L) Mean: 104.7\n- AST (U/L) Median: 102.9\n- Bilirubin (mg/dL) Mean: 2.32\n- Bilirubin (mg/dL) Median: 2.32\n- ALP (U/L) Mean: 81.8\n- ALP (U/L) Median: 62.7\n- Creatinine (mg/dL) Mean: 1.01\n- Creatinine (mg/dL) Median: 0.89\n- BUN (mg/dL) Mean: 15.9\n- BUN (mg/dL) Median: 12.0\n- WBC (K) Mean: 6.1\n- WBC (K) Median: 6.5\n- Platelets (K) Mean: 260\n- Platelets (K) Median: 247\n\n#### Non-Statin Subgroup\n- N: 132\n- ALT (U/L) Mean: 31.3\n- ALT (U/L) Median: 31.2\n- AST (U/L) Mean: 29.1\n- AST (U/L) Median: 28.1\n- Bilirubin (mg/dL) Mean: 0.89\n- Bilirubin (mg/dL) Median: 0.87\n- ALP (U/L) Mean: 58.0\n- ALP (U/L) Median: 69.6\n- Creatinine (mg/dL) Mean: 1.0\n- Creatinine (mg/dL) Median: 0.91\n- BUN (mg/dL) Mean: 17.6\n- BUN (mg/dL) Median: 12.0\n- WBC (K) Mean: 7.5\n- WBC (K) Median: 5.9\n- Platelets (K) Mean: 232\n- Platelets (K) Median: 238\n\n### Adverse Events\n- AE ID: AE-0107, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0108, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0109, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0110, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 46\n- ACE Inhibitor Count: 28\n- Metformin Count: 23\n- PPI Count: 18\n- NSAID Count: 12\n- Other Count: 37\n\n### Protocol Deviations\n- PD ID: PD-053, Description: Concomitant medication not recorded at visit, Severity: minor, Site: site_05\n- PD ID: PD-054, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_07\n- PD ID: PD-055, Description: Informed consent version outdated by 1 revision, Severity: minor, Site: site_03\n\n### Investigator Notes\n- Study drug accountability reconciled, no discrepancies\n- All CRFs current through prior visit cycle\n- Protocol amendment v4.0 submitted to IRB: statin exclusion criterion added, CYP3A4 substrate screening required\n- In-vitro CYP3A4 Ki data received: LNS-4821 Ki = 0.8 uM, consistent with clinical DDI magnitude\n\n### Events\n- CRO quarterly oversight report submitted\n- Site 06 new coordinator onboarding completed\n- Investigator meeting minutes distributed\n- Protocol amendment v4.0 submitted to central IRB\n\n### Notes\n- Week 26: Protocol amendment v4.0 under IRB review/approval. Statin subjects transitioning.",
          "meta": {
            "episode_type": "signal",
            "phase": "root_cause",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_027",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-02T10:00:00",
          "text": "## 2024-09-02 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 218\n- Active: 202\n- Screen Failures Cumulative: 68\n- Withdrawals Cumulative: 16\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 16\n- Site 02 Active: 15\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 20\n- Site 03 Active: 19\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 14\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 18\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 13\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 4\n- Site 07 Enrolled: 24\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 16\n- Site 08 Active: 15\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 14\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 19\n- Site 11 Statin Concomitant: 6\n- Site 12 Enrolled: 16\n- Site 12 Active: 15\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 53\n- ALT (U/L) Mean: 162.5\n- ALT (U/L) Median: 160.5\n- AST (U/L) Mean: 108.1\n- AST (U/L) Median: 106.5\n- Bilirubin (mg/dL) Mean: 2.44\n- Bilirubin (mg/dL) Median: 2.41\n- ALP (U/L) Mean: 69.2\n- ALP (U/L) Median: 55.0\n- Creatinine (mg/dL) Mean: 0.98\n- Creatinine (mg/dL) Median: 0.99\n- BUN (mg/dL) Mean: 17.4\n- BUN (mg/dL) Median: 15.0\n- WBC (K) Mean: 8.2\n- WBC (K) Median: 7.6\n- Platelets (K) Mean: 236\n- Platelets (K) Median: 223\n\n#### Non-Statin Subgroup\n- N: 129\n- ALT (U/L) Mean: 22.1\n- ALT (U/L) Median: 21.7\n- AST (U/L) Mean: 23.2\n- AST (U/L) Median: 21.7\n- Bilirubin (mg/dL) Mean: 0.63\n- Bilirubin (mg/dL) Median: 0.62\n- ALP (U/L) Mean: 52.7\n- ALP (U/L) Median: 53.7\n- Creatinine (mg/dL) Mean: 0.82\n- Creatinine (mg/dL) Median: 0.99\n- BUN (mg/dL) Mean: 13.9\n- BUN (mg/dL) Median: 15.8\n- WBC (K) Mean: 8.0\n- WBC (K) Median: 7.5\n- Platelets (K) Mean: 232\n- Platelets (K) Median: 213\n\n### Adverse Events\n- AE ID: AE-0111, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0112, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0113, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0114, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 38\n- ACE Inhibitor Count: 30\n- Metformin Count: 23\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 32\n\n### Protocol Deviations\n- PD ID: PD-056, Description: Incorrect lab panel order, repeated, Severity: minor, Site: site_10\n- PD ID: PD-057, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_06\n- PD ID: PD-058, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_08\n\n### Investigator Notes\n- Query resolution rate at 94%\n- Central lab results received within 48h turnaround\n- IRB approved protocol amendment v4.0; all sites notified\n- Statin co-administered subjects transitioning off statins per amended protocol\n\n### Events\n- IVRS system update deployed, randomization unaffected\n- Site 10 pharmacy temperature log reviewed: compliant\n- Protocol amendment v4.0 approved; site distribution initiated\n\n### Notes\n- Week 27: Protocol amendment v4.0 under IRB review/approval. Statin subjects transitioning.",
          "meta": {
            "episode_type": "signal",
            "phase": "root_cause",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_028",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-09T10:00:00",
          "text": "## 2024-09-09 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 220\n- Active: 200\n- Screen Failures Cumulative: 48\n- Withdrawals Cumulative: 20\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 16\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 20\n- Site 03 Active: 19\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 15\n- Site 04 Active: 15\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 18\n- Site 05 Active: 17\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 13\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 24\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 8\n- Site 08 Enrolled: 16\n- Site 08 Active: 16\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 15\n- Site 10 Active: 15\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 19\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 16\n- Site 12 Active: 15\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 51\n- ALT (U/L) Mean: 166.2\n- ALT (U/L) Median: 164.2\n- AST (U/L) Mean: 115.1\n- AST (U/L) Median: 113.9\n- Bilirubin (mg/dL) Mean: 2.84\n- Bilirubin (mg/dL) Median: 2.8\n- ALP (U/L) Mean: 67.4\n- ALP (U/L) Median: 79.6\n- Creatinine (mg/dL) Mean: 0.91\n- Creatinine (mg/dL) Median: 0.86\n- BUN (mg/dL) Mean: 12.2\n- BUN (mg/dL) Median: 12.0\n- WBC (K) Mean: 5.6\n- WBC (K) Median: 7.3\n- Platelets (K) Mean: 242\n- Platelets (K) Median: 246\n\n#### Non-Statin Subgroup\n- N: 123\n- ALT (U/L) Mean: 29.1\n- ALT (U/L) Median: 28.5\n- AST (U/L) Mean: 21.3\n- AST (U/L) Median: 20.1\n- Bilirubin (mg/dL) Mean: 0.58\n- Bilirubin (mg/dL) Median: 0.56\n- ALP (U/L) Mean: 57.4\n- ALP (U/L) Median: 49.0\n- Creatinine (mg/dL) Mean: 1.03\n- Creatinine (mg/dL) Median: 0.89\n- BUN (mg/dL) Mean: 12.9\n- BUN (mg/dL) Median: 13.0\n- WBC (K) Mean: 7.8\n- WBC (K) Median: 6.4\n- Platelets (K) Mean: 256\n- Platelets (K) Median: 213\n\n### Adverse Events\n- AE ID: AE-0115, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0116, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0117, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0118, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0119, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 31\n- ACE Inhibitor Count: 28\n- Metformin Count: 22\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 37\n\n### Protocol Deviations\n- PD ID: PD-059, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_07\n- PD ID: PD-060, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_12\n\n### Investigator Notes\n- EDC data entry backlog cleared, queries resolved\n- Study drug accountability reconciled, no discrepancies\n- Regulatory binder audit: all documents current\n- 10 of 12 sites have implemented protocol amendment; 2 sites pending local IRB\n\n### Events\n- Medical monitor weekly call completed\n- Bioanalytical lab shipment tracking confirmed for 4 samples\n- IVRS system update deployed, randomization unaffected\n- Site implementation tracking: 10/12 sites active on amended protocol\n\n### Notes\n- Week 28: Amended protocol in effect at majority of sites. Hepatic monitoring frequency adjusted.",
          "meta": {
            "episode_type": "signal",
            "phase": "root_cause",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_029",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-16T10:00:00",
          "text": "## 2024-09-16 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 222\n- Active: 202\n- Screen Failures Cumulative: 69\n- Withdrawals Cumulative: 20\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 17\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 20\n- Site 03 Active: 20\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 15\n- Site 04 Active: 15\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 18\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 13\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 4\n- Site 07 Enrolled: 24\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 17\n- Site 08 Active: 17\n- Site 08 Statin Concomitant: 5\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 15\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 19\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 17\n- Site 12 Active: 17\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n- Statin Subgroup N: 52\n- Statin Subgroup ALT (U/L) Mean: 171.6\n- Statin Subgroup ALT (U/L) Median: 169.8\n- Statin Subgroup AST (U/L) Mean: 118.2\n- Statin Subgroup AST (U/L) Median: 118.1\n- Statin Subgroup Bilirubin (mg/dL) Mean: 2.77\n- Statin Subgroup Bilirubin (mg/dL) Median: 2.74\n- Statin Subgroup ALP (U/L) Mean: 82.0\n- Statin Subgroup ALP (U/L) Median: 68.1\n- Statin Subgroup Creatinine (mg/dL) Mean: 0.87\n- Statin Subgroup Creatinine (mg/dL) Median: 0.82\n- Statin Subgroup BUN (mg/dL) Mean: 13.3\n- Statin Subgroup BUN (mg/dL) Median: 11.4\n- Statin Subgroup WBC (K) Mean: 8.2\n- Statin Subgroup WBC (K) Median: 5.7\n- Statin Subgroup Platelets (K) Mean: 234\n- Statin Subgroup Platelets (K) Median: 228\n- Non-Statin Subgroup N: 126\n- Non-Statin Subgroup ALT (U/L) Mean: 21.3\n- Non-Statin Subgroup ALT (U/L) Median: 21.0\n- Non-Statin Subgroup AST (U/L) Mean: 19.4\n- Non-Statin Subgroup AST (U/L) Median: 18.3\n- Non-Statin Subgroup Bilirubin (mg/dL) Mean: 0.52\n- Non-Statin Subgroup Bilirubin (mg/dL) Median: 0.49\n- Non-Statin Subgroup ALP (U/L) Mean: 69.3\n- Non-Statin Subgroup ALP (U/L) Median: 68.1\n- Non-Statin Subgroup Creatinine (mg/dL) Mean: 0.85\n- Non-Statin Subgroup Creatinine (mg/dL) Median: 0.91\n- Non-Statin Subgroup BUN (mg/dL) Mean: 16.6\n- Non-Statin Subgroup BUN (mg/dL) Median: 12.7\n- Non-Statin Subgroup WBC (K) Mean: 6.4\n- Non-Statin Subgroup WBC (K) Median: 7.6\n- Non-Statin Subgroup Platelets (K) Mean: 232\n- Non-Statin Subgroup Platelets (K) Median: 258\n\n### Adverse Events\n- AE ID: AE-0120, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0121, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0122, Description: back pain, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0123, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0124, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0125, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: false, Subject Group: statin\n- AE ID: AE-0126, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 23\n- ACE Inhibitor Count: 30\n- Metformin Count: 22\n- PPI Count: 18\n- NSAID Count: 13\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-061, Description: Missed visit window (2 days late), Severity: minor, Site: site_09\n\n### Investigator Notes\n- Source document verification complete for prior monitoring visit\n- Training log updated for new study coordinator\n- All sites now operating under amended protocol v4.0\n\n### Events\n- Site 12 monitoring visit completed, 1 findings\n- Drug accountability audit at Site 05: no discrepancies\n\n### Notes\n- Week 29: Amended protocol in effect at majority of sites. Hepatic monitoring frequency adjusted.",
          "meta": {
            "episode_type": "signal",
            "phase": "root_cause",
            "signal_density": "high"
          }
        },
        {
          "episode_id": "clinical_signal_03_ep_030",
          "scope_id": "clinical_signal_03",
          "timestamp": "2024-09-23T10:00:00",
          "text": "## 2024-09-23 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 224\n- Active: 207\n- Screen Failures Cumulative: 78\n- Withdrawals Cumulative: 17\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 17\n- Site 02 Active: 16\n- Site 02 Statin Concomitant: 5\n- Site 03 Enrolled: 21\n- Site 03 Active: 20\n- Site 03 Statin Concomitant: 6\n- Site 04 Enrolled: 15\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 4\n- Site 05 Enrolled: 19\n- Site 05 Active: 19\n- Site 05 Statin Concomitant: 6\n- Site 06 Enrolled: 13\n- Site 06 Active: 13\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 24\n- Site 07 Active: 23\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 17\n- Site 08 Active: 17\n- Site 08 Statin Concomitant: 5\n- Site 09 Enrolled: 19\n- Site 09 Active: 19\n- Site 09 Statin Concomitant: 6\n- Site 10 Enrolled: 15\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 21\n- Site 11 Active: 21\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 17\n- Site 12 Active: 17\n- Site 12 Statin Concomitant: 4\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 181.8\n- ALT (U/L) Median: 179.2\n- AST (U/L) Mean: 120.0\n- AST (U/L) Median: 119.0\n- Bilirubin (mg/dL) Mean: 3.1\n- Bilirubin (mg/dL) Median: 3.1\n- ALP (U/L) Mean: 57.0\n- ALP (U/L) Median: 75.7\n- Creatinine (mg/dL) Mean: 0.96\n- Creatinine (mg/dL) Median: 0.96\n- BUN (mg/dL) Mean: 16.1\n- BUN (mg/dL) Median: 13.6\n- WBC (K) Mean: 7.8\n- WBC (K) Median: 6.3\n- Platelets (K) Mean: 219\n- Platelets (K) Median: 249\n\n#### Non-Statin Subgroup\n- N: 131\n- ALT (U/L) Mean: 28.8\n- ALT (U/L) Median: 26.9\n- AST (U/L) Mean: 28.3\n- AST (U/L) Median: 27.9\n- Bilirubin (mg/dL) Mean: 0.6\n- Bilirubin (mg/dL) Median: 0.56\n- ALP (U/L) Mean: 67.0\n- ALP (U/L) Median: 64.9\n- Creatinine (mg/dL) Mean: 1.02\n- Creatinine (mg/dL) Median: 0.97\n- BUN (mg/dL) Mean: 14.1\n- BUN (mg/dL) Median: 13.9\n- WBC (K) Mean: 6.3\n- WBC (K) Median: 7.9\n- Platelets (K) Mean: 252\n- Platelets (K) Median: 229\n\n### Adverse Events\n- AE ID: AE-0127, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0128, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0129, Description: headache, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0130, Description: jaundice, Grade: 2, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0131, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n- AE ID: AE-0132, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: false, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 14\n- ACE Inhibitor Count: 29\n- Metformin Count: 22\n- PPI Count: 18\n- NSAID Count: 11\n- Other Count: 32\n\n### Protocol Deviations\n- PD ID: PD-062, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_06\n- PD ID: PD-063, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_03\n\n### Investigator Notes\n- Enrollment on track per protocol timeline\n- All CRFs current through prior visit cycle\n- Post-amendment statin subgroup n=8 (subjects who could not discontinue); hepatic monitoring frequency doubled\n\n### Events\n- Drug accountability audit at Site 05: no discrepancies\n- Investigator meeting minutes distributed\n- End-of-phase safety data compilation initiated for regulatory briefing\n\n### Notes\n- Week 30: Amended protocol in effect at majority of sites. Hepatic monitoring frequency adjusted.",
          "meta": {
            "episode_type": "signal",
            "phase": "root_cause",
            "signal_density": "high"
          }
        }
      ]
    }
  ],
  "questions": [
    {
      "question_id": "cs03_q01_longitudinal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 12,
      "question_type": "longitudinal",
      "prompt": "Based on the trial data so far, are there any emerging safety signals in the lab panels?",
      "ground_truth": {
        "canonical_answer": "ALT values are creeping upward in a subset of patients, specifically those on concomitant statin therapy. The elevations are still below protocol action thresholds but the trend across multiple weeks is notable.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver"
        ]
      }
    },
    {
      "question_id": "cs03_q02_null",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 12,
      "question_type": "null_hypothesis",
      "prompt": "What was the enrollment count at Site 03 in the Week 6 summary?",
      "ground_truth": {
        "canonical_answer": "The enrollment figure as documented in the Week 6 site summary.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_006"
        ],
        "key_facts": []
      }
    },
    {
      "question_id": "cs03_q03_longitudinal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "longitudinal",
      "prompt": "What is driving the hepatic adverse events in this trial?",
      "ground_truth": {
        "canonical_answer": "A drug-drug interaction between LNS-4821 and concomitant statin therapy (atorvastatin) via CYP3A4 inhibition. The hepatotoxicity signal is in the statin subgroup across all sites, not a site-specific lab issue. The Site 07 equipment hypothesis was a red herring.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_023",
          "clinical_signal_03_ep_015"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge"
        ]
      }
    },
    {
      "question_id": "cs03_q04_action",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 30,
      "question_type": "action_recommendation",
      "prompt": "What protocol amendments should the DSMB recommend?",
      "ground_truth": {
        "canonical_answer": "Exclude concomitant statin use from the trial. Add CYP3A4 interaction screening. Implement more frequent hepatic panel monitoring for enrolled subjects. Consider dose adjustment studies for the LNS-4821/statin interaction.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_019",
          "clinical_signal_03_ep_023",
          "clinical_signal_03_ep_026"
        ],
        "key_facts": [
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver"
        ]
      }
    },
    {
      "question_id": "cs03_q05_negative",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 15,
      "question_type": "negative",
      "prompt": "Is there evidence of nephrotoxicity or renal dysfunction in enrolled subjects?",
      "ground_truth": {
        "canonical_answer": "No. Renal panels (creatinine, BUN, eGFR) remain within normal limits throughout the trial. The emerging safety signal is hepatic, not renal.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_004",
          "clinical_signal_03_ep_011"
        ],
        "key_facts": [
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    {
      "question_id": "cs03_q06_paraphrase",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "paraphrase",
      "prompt": "Why are liver enzymes elevated in a subset of trial participants?",
      "ground_truth": {
        "canonical_answer": "A drug-drug interaction between LNS-4821 and concomitant statin therapy (atorvastatin) via CYP3A4 inhibition. The hepatotoxicity signal is in the statin subgroup across all sites, not a site-specific lab issue. The Site 07 equipment hypothesis was a red herring.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_023",
          "clinical_signal_03_ep_015"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations"
        ]
      }
    },
    {
      "question_id": "cs03_q07_temporal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "temporal",
      "prompt": "When did ALT elevations first become apparent, and how many weeks elapsed before subjects met Hy's Law criteria?",
      "ground_truth": {
        "canonical_answer": "ALT elevations in the statin subgroup first became apparent during the early signal phase. It took approximately 7-13 weeks from initial detection to subjects meeting Hy's Law criteria (ALT >3x ULN + bilirubin >2x ULN) during the escalation phase.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013",
          "clinical_signal_03_ep_017"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    {
      "question_id": "cs03_q08_counterfactual",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "counterfactual",
      "prompt": "If the Site 07 lab equipment calibration issue were responsible for the ALT elevations, what pattern would you expect across sites? Does that match the data?",
      "ground_truth": {
        "canonical_answer": "If Site 07 equipment were the cause, ALT elevations would be confined to Site 07 and resolve after recalibration. Instead, the ALT signal appears across multiple sites and correlates with statin co-administration, not site. The cross-site pattern rules out a site-specific equipment explanation.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_015",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_024"
        ],
        "key_facts": [
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    {
      "question_id": "cs03_q09_longitudinal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 5,
      "question_type": "longitudinal",
      "prompt": "Based on the first five weeks of trial data, are there any safety signals in the lab panels?",
      "ground_truth": {
        "canonical_answer": "No. All lab panels are within normal limits across all sites. Hepatic, renal, and hematology markers show no adverse trends. The trial is in the enrollment ramp-up phase.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_003",
          "clinical_signal_03_ep_005"
        ],
        "key_facts": []
      }
    },
    {
      "question_id": "cs03_q10_evidence",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 5,
      "question_type": "evidence_sufficiency",
      "prompt": "Is there sufficient data at this point to evaluate the safety profile of LNS-4821?",
      "ground_truth": {
        "canonical_answer": "No. Only 5 weeks of data from the enrollment ramp phase are available. The subject population is too small and exposure duration too short to draw conclusions about the drug's safety profile.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_003"
        ],
        "key_facts": []
      }
    },
    {
      "question_id": "cs03_q11_longitudinal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "longitudinal",
      "prompt": "What is the emerging safety profile of LNS-4821, and which patient subgroup is most affected?",
      "ground_truth": {
        "canonical_answer": "Hepatotoxicity in the statin co-administered subgroup. ALT elevations reaching 2-3x ULN across multiple sites, with two subjects meeting Hy's Law criteria. Non-statin patients remain stable. The cross-site distribution rules out the Site 07 equipment hypothesis.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_017",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_019"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge"
        ]
      }
    },
    {
      "question_id": "cs03_q12_severity",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "severity_assessment",
      "prompt": "How would you assess the severity of the hepatic signal and the urgency of protocol intervention?",
      "ground_truth": {
        "canonical_answer": "High severity. Two subjects have met Hy's Law criteria (ALT >3x ULN + bilirubin >2x ULN), which is a recognized indicator of potential drug-induced liver injury. The signal is escalating and protocol amendment is urgent to prevent further SAEs.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_017",
          "clinical_signal_03_ep_019"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    {
      "question_id": "cs03_q13_paraphrase",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 12,
      "question_type": "paraphrase",
      "prompt": "Are any laboratory parameters trending outside normal limits in specific patient populations?",
      "ground_truth": {
        "canonical_answer": "ALT values are creeping upward in a subset of patients, specifically those on concomitant statin therapy. The elevations are still below protocol action thresholds but the trend across multiple weeks is notable.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver"
        ]
      }
    },
    {
      "question_id": "cs03_q14_paraphrase",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "paraphrase",
      "prompt": "Why is there a difference in liver enzyme levels between patient subgroups?",
      "ground_truth": {
        "canonical_answer": "A drug-drug interaction between LNS-4821 and concomitant statin therapy via CYP3A4 inhibition causes hepatotoxicity in the statin subgroup. The signal appears across all sites, not just Site 07, ruling out the equipment calibration hypothesis.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_023",
          "clinical_signal_03_ep_015"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations"
        ]
      }
    },
    {
      "question_id": "cs03_q15_negative",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "negative",
      "prompt": "Is there evidence of an immune-mediated reaction or immunogenicity issues with LNS-4821?",
      "ground_truth": {
        "canonical_answer": "No. Immunogenicity markers and antibody responses are not related to the hepatic safety signal. The mechanism is a pharmacokinetic drug-drug interaction via CYP3A4, not an immune-mediated reaction.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_005",
          "clinical_signal_03_ep_012"
        ],
        "key_facts": [
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity"
        ]
      }
    },
    {
      "question_id": "cs03_q16_negative",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "negative",
      "prompt": "Are there musculoskeletal or pain-related adverse events associated with LNS-4821?",
      "ground_truth": {
        "canonical_answer": "No. Pain and musculoskeletal endpoints show no drug-related adverse trends. The safety signal is hepatic, confined to the statin co-administered subgroup.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_006",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    {
      "question_id": "cs03_q17_temporal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "temporal",
      "prompt": "How rapidly are ALT values escalating in the affected subgroup?",
      "ground_truth": {
        "canonical_answer": "ALT values in the statin subgroup have progressed from baseline normal (15-35 U/L) through subtle elevation (45-65 U/L) to clinically significant levels (80-120 U/L, 2-3x ULN) over the course of the signal and escalation phases. The rate of increase has accelerated.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_017",
          "clinical_signal_03_ep_019"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns"
        ]
      }
    },
    {
      "question_id": "cs03_q18_temporal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 15,
      "question_type": "temporal",
      "prompt": "When did the first hepatic enzyme elevations appear relative to drug exposure initiation?",
      "ground_truth": {
        "canonical_answer": "Hepatic enzyme elevations first appeared during the early signal phase, approximately weeks 9-10 of the trial, several weeks after subjects began receiving LNS-4821 with concomitant statin therapy.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    {
      "question_id": "cs03_q19_distractor",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 15,
      "question_type": "distractor_resistance",
      "prompt": "Are novel urinary biomarkers (KIM-1, NGAL) showing any abnormalities in trial subjects?",
      "ground_truth": {
        "canonical_answer": "No. Renal biomarkers remain within normal limits. The emerging safety signal is hepatic (ALT/AST elevation), not renal.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_004",
          "clinical_signal_03_ep_011"
        ],
        "key_facts": [
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    {
      "question_id": "cs03_q20_distractor",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "distractor_resistance",
      "prompt": "Is there any relationship between seroconversion rates and the adverse event pattern?",
      "ground_truth": {
        "canonical_answer": "No. Immunogenicity measures including seroconversion rates are not related to the hepatotoxicity signal. The adverse events are driven by a CYP3A4-mediated drug-drug interaction with statins.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_005",
          "clinical_signal_03_ep_023"
        ],
        "key_facts": [
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity"
        ]
      }
    },
    {
      "question_id": "cs03_q21_distractor",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "distractor_resistance",
      "prompt": "Are VAS pain scores or functional assessments correlating with the laboratory abnormalities?",
      "ground_truth": {
        "canonical_answer": "No. Pain endpoints are stable and unrelated to the hepatic safety signal. The ALT elevations correlate with statin co-administration, not pain or functional measures.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_006",
          "clinical_signal_03_ep_017"
        ],
        "key_facts": [
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    {
      "question_id": "cs03_q22_counterfactual",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "counterfactual",
      "prompt": "If the ALT elevations were caused by a viral hepatitis outbreak among trial subjects, what pattern would you expect? Does the data match?",
      "ground_truth": {
        "canonical_answer": "Viral hepatitis would show clustered onset at specific sites, associated symptoms (fatigue, jaundice), and positive viral serologies. Instead, the elevations are distributed across sites and correlate with statin co-administration, not geography or viral exposure. The pattern is consistent with a pharmacokinetic interaction, not infection.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_019"
        ],
        "key_facts": [
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    {
      "question_id": "cs03_q23_null",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 20,
      "question_type": "null_hypothesis",
      "prompt": "How many protocol deviations were reported at Site 03 in the most recent weekly summary?",
      "ground_truth": {
        "canonical_answer": "The protocol deviation count as documented in the weekly site summary.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_018"
        ],
        "key_facts": []
      }
    },
    {
      "question_id": "cs03_q24_evidence",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 15,
      "question_type": "evidence_sufficiency",
      "prompt": "Is there sufficient evidence at this point to convene a DSMB safety review?",
      "ground_truth": {
        "canonical_answer": "Borderline. The ALT trend in the statin subgroup is concerning but individual values are still below protocol action thresholds. A few more weeks of data showing continued escalation would strengthen the case for DSMB review.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge"
        ]
      }
    }
  ]
}